

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	9	MAR 22	EMBASE is now updated on a daily basis
NEWS	10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	12	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS	16	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	17	MAY 11	KOREAPAT updates resume
NEWS	18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	20	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	21	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:38:40 ON 15 JUN 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:38:47 ON 15 JUN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2006 HIGHEST RN 887828-19-5

DICTIONARY FILE UPDATES: 14 JUN 2006 HIGHEST RN 887828-19-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10083245a.str



```

chain nodes :
10 11 12 16
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-10 7-16 10-11 10-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-16 8-9 10-12
exact bonds :
10-11

```

G1:Cb,Cy,Hy

G2:C,Cb,Cy,Ak

G3:A,Cb,Cy,Hy

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 16:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Cy,Hy

G2 C,Cb,Cy,Ak

G3 A,Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:39:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 616 TO ITERATE

100.0% PROCESSED 616 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 10831 TO 13809

PROJECTED ANSWERS: 736 TO 1664

L2 50 SEA SSS SAM L1

=> s l2 full

FULL SEARCH INITIATED 18:39:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 12864 TO ITERATE

100.0% PROCESSED 12864 ITERATIONS

1059 ANSWERS

SEARCH TIME: 00.00.01

L3 1059 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 18:39:28 ON 15 JUN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2006 VOL 144 ISS 25
FILE LAST UPDATED: 14 Jun 2006 (20060614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 63 L3

=> d 14 ibib hitstr abs 1-63

L4 ANSWER 1 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:382981 CAPLUS
 DOCUMENT NUMBER: 144:432830
 TITLE: Preparation of pyrazolo[1,5-a]pyrimidines as
 corticotropin-releasing factor (CRF) receptor
 antagonists.
 INVENTOR(S): Lanier, Marion; Luo, Zhiyong; Moorjani, Manisha;
 Tellew, John Edward; Williams, John P.; Zhang, Xiaohu
 PATENT ASSIGNEE(S): Sb Pharmco Puerto Rico Inc., P. R.; Neurocrine
 Biosciences Inc.
 SOURCE: PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2006044958	A1	20060427	WO 2005-US37576	20051019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-620060P P 20041019
 GB 2005-19957 A 20050930


IT 885220-17-7P 885220-18-8P 885220-19-9P
 885220-20-2P 885220-21-3P 885220-22-4P
 885220-23-5P 885220-24-6P 885220-25-7P
 885220-26-8P 885220-27-9P 885220-28-0P
 885220-29-1P 885220-30-4P 885220-31-5P
 885220-32-6P 885220-33-7P 885220-35-9P
 885220-36-0P 885220-37-1P 885220-38-2P
 885220-41-7P 885220-42-8P 885220-44-0P
 885220-45-1P 885220-46-2P 885220-47-3P
 885220-48-4P 885220-49-5P 885220-50-8P
 885220-51-9P 885220-52-0P 885220-53-1P
 885220-54-2P 885220-55-3P 885220-56-4P
 885220-57-5P 885220-58-6P 885220-59-7P
 885220-60-0P 885220-61-1P 885220-62-2P
 885220-64-4P 885220-70-2P 885220-71-3P
 885220-72-4P 885220-73-5P 885220-74-6P
 885220-75-7P 885220-76-8P 885220-79-1P
 885220-80-4P 885220-81-5P 885220-82-6P
 885220-83-7P 885220-84-8P 885220-85-9P
 885220-86-0P 885220-87-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of pyrazolopyrimidines as CRF receptor
 antagonists)


RN 885220-17-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 885220-18-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]propyl]- (9CI) (CA INDEX NAME)




RN 885220-19-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)-2-phenylethyl]- (9CI) (CA INDEX NAME)




RN 885220-20-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (9CI) (CA INDEX NAME)




RN 885220-21-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (9CI) (CA INDEX NAME)




RN 885220-22-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 885220-23-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 885220-24-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1R)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 885220-25-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 885220-26-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]propyl]- (9CI)
 (CA INDEX NAME)




RN 885220-27-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 885220-28-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropyl]- (9CI) (CA INDEX NAME)



RN 885220-29-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(3-ethyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 885220-30-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(3-propyl-1,2,4-oxadiazol-5-yl)methyl]- (9CI) (CA INDEX NAME)



RN 885220-31-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]cyclopropyl]-(9CI) (CA INDEX NAME)



RN 885220-32-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-33-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-[(1R)-3-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-35-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)




RN 885220-36-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 885220-37-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (9CI) (CA INDEX NAME)




RN 885220-38-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[3-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (9CI) (CA INDEX NAME)




RN 885220-41-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)



RN 885220-42-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 885220-44-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]- (9CI) (CA INDEX NAME)




RN 885220-45-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 885220-46-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 885220-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-methyl-2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-49-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-50-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]propyl]- (9CI) (CA INDEX NAME)




RN 885220-51-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]propyl]-3-(2,4-dimethoxyphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 885220-52-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]propyl]- (9CI) (CA INDEX NAME)



RN 885220-53-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885220-54-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]-(9CI) (CA INDEX NAME)



RN 885220-55-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-56-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-58-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-59-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-
 [(1S)-2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-60-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-
 [(1S)-2,2,2-trifluoro-1-[[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-61-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-
 dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 885220-62-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-64-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-70-2 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 885220-71-3 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]propyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 885220-72-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]propyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 885220-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-74-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1R)-2-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-75-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-76-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-79-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(1,3,4-oxadiazol-2-yl)propyl]- (9CI) (CA INDEX NAME)




RN 885220-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(5-methyl-1,3,4-oxadiazol-2-yl)propyl]- (9CI) (CA INDEX NAME)




RN 885220-81-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 885220-82-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]ethyl]-(9CI) (CA INDEX NAME)




RN 885220-83-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-(9CI) (CA INDEX NAME)




RN 885220-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)




RN 885220-85-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-chloro-4-fluorophenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)




RN 885220-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)



RN 885220-87-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-chloro-4-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)




IT 885221-15-8P 885221-16-9P 885221-18-1P
 885221-19-2P 885221-20-5P 885221-21-6P
 885221-22-7P 885221-23-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)

RN 885221-15-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-
 dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX
 NAME)



RN 885221-16-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-
 pyridinyl]-2,5-dimethyl-N-[(1S)-3-methyl-1-(3-methyl-1,2,4-oxadiazol-5-
 yl)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-18-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-19-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 885221-20-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 885221-21-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-22-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 885221-23-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)




IT 885220-94-0P 885220-95-1P 885220-96-2P
 885220-97-3P 885220-98-4P 885220-99-5P
 885221-02-3P 885221-03-4P 885221-04-5P
 885221-05-6P 885221-06-7P 885221-08-9P
 885221-09-0P 885221-10-3P 885221-11-4P
 885221-12-5P 885221-13-6P 885221-14-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 885220-94-0 CAPLUS

CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 885220-95-1 CAPLUS

CN Butanoic acid, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 885220-96-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 885220-97-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 885220-98-4 CAPLUS
CN Ethanimidamide, N-[(2S)-2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-oxobutoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885220-99-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 885220-61-1

CMF C22 H26 N6 O2


Absolute stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 885221-02-3 CAPLUS

CN Butanenitrile, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-03-4 CAPLUS

CN Butanoic acid, 4,4,4-trifluoro-3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-04-5 CAPLUS

CN Butanoic acid, 4,4,4-trifluoro-3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-05-6 CAPLUS

CN Butanamide, 4,4,4-trifluoro-3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 885221-06-7 CAPLUS

CN Butanenitrile, 4,4,4-trifluoro-3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 885221-08-9 CAPLUS
 CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, hydrazide (9CI) (CA INDEX NAME)



RN 885221-09-0 CAPLUS
 CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 2-formylhydrazide (9CI) (CA INDEX NAME)




RN 885221-10-3 CAPLUS
 CN Butanoic acid, 2-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 2-acetylhydrazide (9CI) (CA INDEX NAME)




RN 885221-11-4 CAPLUS

CN Butaneperoxoic acid, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 885221-12-5 CAPLUS

CN Butanoic acid, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, hydrazide (9CI) (CA INDEX NAME)




RN 885221-13-6 CAPLUS

CN Butanoic acid, 3-[[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 2-acetylhydrazide (9CI) (CA INDEX NAME)




RN 885221-14-7 CAPLUS

CN Butanoic acid, 2-[[3-(2-chloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R1 = H, (substituted) alkyl, haloalkyl, alkoxyalkyl, aralkyl, heterocycloalkyl; R2a, R2b = H, (substituted) alkyl, haloalkyl, aralkyl, alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl; R1R2a, R1R2b = atoms to form 4-7 membered ring; Y = bond, C(R4aR4b)m; m = 1, 2; R4a, R4b = H, (substituted) alkyl, aralkyl, alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl; R4aR4bC = atoms to form a 3-7 membered ring; Het = (substituted) oxadiazolyl; n = 0-3; R6 = H, (substituted) alkyl; R7 = H, (substituted) alkyl, alkoxy, amino, alkylsulfonyl; p = 0-3; Ar = Ph, pyridyl], were prepared. Thus, [3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]amine (multistep preparation given) showed CRF receptor binding affinity with $K_i < 100$ nM.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:170572 CAPLUS
DOCUMENT NUMBER: 144:254146
TITLE: Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 64 pp., Cont.-in-part of U.S. Ser. No. 654,157.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006040958	A1	20060223	US 2005-244776	20051006
US 2004102451	A1	20040527	US 2003-654157	20030903
PRIORITY APPLN. INFO.:			US 2002-408030P	P 20020904
			US 2003-654157	A2 20030903

OTHER SOURCE(S): MARPAT 144:254146


IT 877380-20-6P 877380-21-7P 877380-23-9P
877380-24-0P 877380-25-1P 877380-26-2P
877380-27-3P 877380-28-4P 877380-29-5P
877380-30-8P 877380-31-9P 877380-32-0P
877380-33-1P 877380-34-2P 877380-35-3P
877380-36-4P 877380-37-5P 877380-38-6P
877380-39-7P 877380-40-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors for treatment and prevention of diseases)


RN 877380-20-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-methyl-5-isothiazolyl)-3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)- (9CI) (CA INDEX NAME)




RN 877380-21-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(4-piperidinyl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-23-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(3-pyrrolidinyl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-24-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(2-pyrrolidinyl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-25-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[5-[[3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-3-isothiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 877380-26-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[5-[[3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-3-isothiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 877380-27-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(tetrahydro-2-furanyl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-28-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(tetrahydro-3-furanyl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-29-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-(piperidinyl)-N-[3-(tetrahydro-3-thienyl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-30-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-(piperidinyl)-N-[3-(tetrahydro-2-thienyl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-31-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(2-piperidinyl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-32-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(3-piperidinyl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-33-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[5-[[3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-3-isothiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 877380-34-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[5-[[3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-3-isothiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 877380-35-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(tetrahydro-2H-pyran-2-yl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-36-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(tetrahydro-2H-pyran-3-yl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-37-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(tetrahydro-2H-pyran-4-yl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-38-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(tetrahydro-2H-thiopyran-2-yl)-5-isothiazolyl]- (9CI) (CA INDEX NAME)




RN 877380-39-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(tetrahydro-2H-thiopyran-3-yl)-5-isothiazolyl]- (9CI)
(CA INDEX NAME)




RN 877380-40-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)-N-[3-(tetrahydro-2H-thiopyran-4-yl)-5-isothiazolyl]- (9CI)
(CA INDEX NAME)



GI



AB The title compds. I [R18 = alkyl or heterocyclyl (wherein heterocyclyl is linked to the isothiazole ring via a carbon atom on heterocyclyl)], useful as inhibitors of cyclin dependent kinases, were prepared Thus, reacting II (preparation given) with 5-amino-3-methylisothiazole hydrochloride followed by treating with Boc2O, coupling of the resulting intermediate with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and Boc-deprotection afforded I [R18 = Me]. The compds. I are tested in in vitro cyclin E/CDK2 kinase assay (no data given). The invention also provides pharmaceutical compns. containing one or more compds. I, methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns.

L4 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:167936 CAPLUS

DOCUMENT NUMBER: 144:254145

TITLE: Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 653,776.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006041131	A1	20060223	US 2005-244772	20051006
US 2004106624	A1	20040603	US 2003-653776	20030903
PRIORITY APPLN. INFO.:			US 2002-408029P	P 20020904
			US 2003-653776	A2 20030903

OTHER SOURCE(S): MARPAT 144:254145


IT 676366-14-6P 877173-69-8P 877173-71-2P
877173-73-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors for treatment and prevention of diseases)


RN 676366-14-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-cyclopropyl-N-[4-(methylsulfonyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 877173-69-8 CAPLUS

CN 1,3-Benzenediamine, N,N-dimethyl-N'-[3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 877173-71-2 CAPLUS

CN Phenol, 4-[[3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)





RN 877173-73-4 CAPLUS

CN 1,3-Benzenediamine, N,N-dimethyl-N'-[3-(1-methyl-1H-pyrazol-4-yl)-5-(3-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. I [R = aryl optionally substituted with one or more heteroaryl; R2 = alkyl, cycloalkyl, CF3, etc.; R3 = H, halo, alkyl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases, were prepared. Thus, reacting II (preparation given) with 4-methylsulfonylaniline hydrochloride in the presence of iPr2NEt afforded 23% III. The compds. I were tested in in vitro cyclin E/CDK2 kinase assay (biol. data given for representative compds. I). The invention also provides pharmaceutical compns. containing one or more compds. I, methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns.

L4 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:152759 CAPLUS

DOCUMENT NUMBER: 144:233090

TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives as MAPKAP-K2 inhibitors

INVENTOR(S): Kosugi, Tomomi; Imai, Minoru; Makino, Hiroaki; Takakuwa, Mika; Unoki, Gen; Kataoka, Kenichiro; Mitchell, Dale Robert; Simpson, Donald James; Harris, Clifford John; Le, Joelle; Yamakoshi, Yuko

PATENT ASSIGNEE(S): Teijin Pharma Limited, Japan

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006016715	A1	20060216	WO 2005-JP15031	20050811
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: JP 2004-236035 A 20040813

OTHER SOURCE(S): MARPAT 144:233090

IT 876389-72-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as MAPKAP-K2 inhibitors)


RN 876389-72-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-[(cis-4-aminocyclohexyl)oxy]-3-cyclopropyl-N-(4-ethoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



AB The title compds. I [R1 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R2 = H, halo, CN, etc.; R3 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; R4 = H, halo, (un)substituted alkyl, etc.; R5 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; Y = O, S; a proviso is given] are prepared I are useful in the treatment of MAPKAP-K2 mediated diseases, for example, inflammatory diseases, autoimmune diseases, osteoclastic disorder, etc. Thus, (dl)-(4-ethoxyphenyl)-[6-methyl-5-(trans-4-propylpiperidin-3-yloxy)pyrazolo[1,5-a]pyrimidin-7-yl]amine was prepared by catalytic hydrogenation of (dl)-trans-4-Allyl-3-[7-(4-ethoxyphenylamino)-6-methylpyrazolo[1,5-a]pyrimidin-5-yloxy]piperidine-1-carboxylic acid benzyl ester. Many compds. of this invention showed IC50 values $\leq 2 \mu\text{M}$ against MAPKAP-K2 (mitogen activated protein kinase-activated protein kinase-2).

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:1026952 CAPLUS
 DOCUMENT NUMBER: 143:326389
 TITLE: Preparation of tricyclic heterocyclic compound as CRF antagonist
 INVENTOR(S): Nakai, Hisao; Saito, Tetsuji; Katsumata, Seishi
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087775	A1	20050922	WO 2005-JP4875	20050314
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2004-72482 A 20040315

OTHER SOURCE(S): MARPAT 143:326389

IT 865188-55-2P 865188-56-3P 865188-57-4P
 865188-58-5P 865188-59-6P 865188-60-9P
 865188-62-1P 865188-76-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclopenta[d]pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidines as CRF antagonist)


RN 865188-55-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-2-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865188-56-3 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2,7-dimethyl- (9CI) (CA INDEX NAME)




RN 865188-57-4 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-2-methyl-N-(1-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 865188-58-5 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-2-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865188-59-6 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-2-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865188-60-9 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-2-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865188-62-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-2-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 865188-76-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2,6,6-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI



AB Title compds. represented by the formula I [wherein ring = (un)substituted tricyclic heterocyclyl; R1 = (un)substituted alkyl, alkenyl, alkynyl etc.; Z = (un)substituted amino, carbon, O, etc.; R2 = (un)substituted unsatd. cyclic group; or ZR2 = (un)substituted cyclyl; and their derivs., N-oxides, pharmaceutically acceptable salts or prodrugs thereof] were prepared as CRF (corticotropin-releasing corticotropin-releasing factor) antagonist. For example, II was produced in a multi-step synthesis starting from the reaction of 1H-pyrazole-3-amine with di-Et allylmalonate. In CRF (corticotropin-releasing factor) binding assays, compds. I exhibited the IC50 values of <1 μ M. Thus, I and their pharmaceutical compns. are useful for the treatment of neuropsychiatric diseases and digestive diseases (no data).

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:962049 CAPLUS

DOCUMENT NUMBER: 143:254020

TITLE: Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists

INVENTOR(S): Romano, Steven Joseph

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079807	A1	20050901	WO 2005-IB251	20050201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2005209250	A1	20050922	US 2005-58329	20050214
PRIORITY APPLN. INFO.:			US 2004-544731P	P 20040213


OTHER SOURCE(S): MARPAT 143:254020

IT 202579-62-2 202579-64-4 203924-40-7
203924-41-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists)


RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 203924-40-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 203924-41-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-5-methyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



AB The present invention is directed to a pharmaceutical compns. for treating, for example, mood disorders or conditions, psychotic disorders or conditions, or a combination thereof, in a mammal such as a human, the composition comprising (a) an atypical antipsychotic, a prodrug thereof or a pharmaceutically acceptable salt of the atypical antipsychotic or prodrug thereof, (b) a corticotropin releasing factor antagonist, a prodrug thereof, or pharmaceutically acceptable salt of said corticotropin releasing factor antagonist or prodrug thereof, and optionally (c) a pharmaceutically acceptable vehicle, carrier or diluent. A pharmaceutical composition is prepared containing ziprasidone with a corticotropin releasing factor antagonist such a 4-(1-ethylproppoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)pyridine.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:904340 CAPLUS
DOCUMENT NUMBER: 143:248405
TITLE: Preparation of pyrazolopyrimidines as agrochemical fungicides
INVENTOR(S): Gebauer, Olaf; Gayer, Herbert; Heinemann, Ulrich; Herrmann, Stefan; Hillebrand, Stefan; Elbe, Hans-ludwig; Ebbert, Ronald; Wachendorff-Neumann, Ulrike; Dahmen, Peter; Kuck, Karl-Heinz
PATENT ASSIGNEE(S): Germany
SOURCE: U.S. Pat. Appl. Publ., 71 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005187224	A1	20050825	US 2005-63191	20050222
DE 102004008807	A1	20050908	DE 2004-102004008807	20040220
WO 2005082907	A2	20050909	WO 2005-EP1694	20050218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: DE 2004-102004008807A 20040220

OTHER SOURCE(S): MARPAT 143:248405


IT 863425-91-6P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolopyrimidines as agrochem. fungicides)

RN 863425-91-6 CAPLUS

CN 1,3,4-Oxathiazol-2-one, 5-[5-chloro-6-(2-chloro-4-fluorophenyl)-7-[(1R)-1,2,2-trimethylpropyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 863425-03-0P 863425-04-1P 863425-05-2P
 863425-92-7P 863425-93-8P 863425-94-9P
 863425-95-0P 863426-20-4P 863426-57-7P
 863426-58-8P 863426-70-4P 863426-71-5P
 863426-72-6P 863427-76-3P 863427-77-4P
 863427-79-6P 863427-80-9P 863428-78-8P
 863428-91-5P 863428-95-9P 863428-96-0P
 863428-97-1P 863431-64-5P 863431-69-0P
 863431-70-3P 863431-77-0P 863456-05-7P
 863456-08-0P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as agrochem. fungicides)


RN 863425-03-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4-dichlorophenyl)-3-(2-pyridinyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 863425-04-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4-dichlorophenyl)-3-(5-methyl-1H-1,2,4-triazol-3-yl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 863425-05-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4-dichlorophenyl)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 863425-92-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(2-pyridinyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 863425-93-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(5-methyl-1H-1,2,4-triazol-3-yl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 863425-94-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-amino-1,3,4-thiadiazol-2-yl)-5-chloro-6-(2-chloro-4-fluorophenyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 863425-95-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 863426-20-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(2-oxazolyl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 863426-57-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-(5-methyl-1H-1,2,4-triazol-3-yl)-6-phenyl-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 863426-58-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-(5-methyl-1,3,4-oxadiazol-2-yl)-6-phenyl-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 863426-70-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4-dichlorophenyl)-N-(1,2-dimethylpropyl)-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 863426-71-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4-dichlorophenyl)-N-(1,2-dimethylpropyl)-3-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)




RN 863426-72-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4-dichlorophenyl)-N-(1,2-dimethylpropyl)-3-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 863427-76-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-N-(1,2-dimethylpropyl)-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 863427-77-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-N-(1,2-dimethylpropyl)-3-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)




RN 863427-79-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-amino-1,3,4-thiadiazol-2-yl)-5-chloro-6-(2-chloro-4-fluorophenyl)-N-(1,2-dimethylpropyl)- (9CI) (CA INDEX NAME)



RN 863427-80-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-N-(1,2-dimethylpropyl)-3-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 863428-78-8 CAPLUS

CN 1,3,4-Oxathiazol-2-one, 5-[5-chloro-7-[(1R)-1,2-dimethylpropyl]amino]-6-(3-methyl-2-thienyl)pyrazolo[1,5-a]pyrimidin-3-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 863428-91-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-(3-methyl-2-thienyl)-3-(2-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 863428-95-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1,2-dimethylpropyl)-6-phenyl-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 863428-96-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1,2-dimethylpropyl)-3-(5-methyl-1H-1,2,4-triazol-3-yl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 863428-97-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1,2-dimethylpropyl)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 863431-64-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(5,6-dihydro-2H-1,2,4-oxadiazin-3-yl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 863431-69-0 CAPLUS
 CN 1,3,4-Oxathiazol-2-one, 5-[5-chloro-7-[(1,2-dimethylpropyl)amino]-6-(3-methyl-2-thienyl)pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 863431-70-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1,2-dimethylpropyl)-6-(3-methyl-2-thienyl)-3-(2-oxazolyl)- (9CI) (CA INDEX NAME)




RN 863431-77-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(5,6-dihydro-1,4,2-dioxazin-3-yl)-N-[(1R)-1,2,2-trimethylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 863456-05-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(2H-1,2,4-oxadiazin-3-yl)-N-[(1R)-1,2,2-trimethylpropyl]-, (6R)- (9CI)
 (CA INDEX NAME)



RN 863456-08-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(2H-1,2,4-oxadiazin-3-yl)-N-[(1R)-1,2,2-trimethylpropyl]-, (6S)- (9CI)
 (CA INDEX NAME)



GI



AB The invention relates to pyrazolopyrimidines I [R1 = H, OH, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, alkoxy, amino; R2 = H, alkyl; NR1R2 may form heterocyclic ring; R3 = halo, optionally substituted aryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl, amino, C1-8 alkoxy, C1-8 alkylthio, C6-10 aryloxy, C6-10 arylthio, heterocyclloxy, etc.; R4 = CONR6R7, CONR7NR72, CONR7OR7, CO2R8, C(S)OR7, C(O)SR7, CS2R7, SR7, SOR7, SO2R7, SO3R7, SONR72, SO2NR72, PO3R72, NR7OR7, B(OR7)2, aromatic, heterocyclyl; X = halo, CN, OH, optionally substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; R5 = H, halo, alkoxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, optionally substituted alkyl, cycloalkyl; R7 = independently H, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl; R8 = H, cation, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aralkyl] and agrochem. active salts thereof, a process for preparing these compds., and to their use for controlling unwanted microorganisms. Thus, cyclocondensation of di-Me cyclopentylmalonate with Me 5-amino-1H-pyrazole-3-carboxylate gave dihydroxypyrazolopyrimidine II. Chlorination of II with POCl3 gave the dichloro derivative, which underwent substitution with (R)-3-methyl-2-butylamine, followed by hydrolysis to give title compound I [R1 = (R)-3-methyl-2-Bu, R2 = R5 = H, R3 = cyclopentyl, R4 = CO2H, X = Cl]. The prepared compds. were tested for fungicidal activity on apples, beans, rice, tomatoes, and wheat.

L4 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:612294 CAPLUS

DOCUMENT NUMBER: 143:133390

TITLE: Preparation of pyrazolopyrimidines as CRF receptor antagonists

INVENTOR(S): Luo, Zhiyong; Slee, Deborah; Tellew, John Edward; Williams, John; Zhang, Xiahou

PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063756	A1	20050714	WO 2004-IB4293	20041220
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-532044P P 20031222


OTHER SOURCE(S): MARPAT 143:133390

IT 858521-24-1P 858523-08-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolopyrimidines as CRF receptor antagonists)

RN 858521-24-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 858523-08-7 CAPLUS

CN Butanoic acid, 2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 858520-82-8P 858520-95-3P 858520-97-5P
 858520-99-7P 858521-01-4P 858521-02-5P
 858521-18-3P 858521-42-3P 858521-51-4P
 858521-52-5P 858521-53-6P 858521-57-0P
 858521-58-1P 858521-59-2P 858521-60-5P
 858521-61-6P 858521-62-7P 858521-63-8P
 858521-64-9P 858521-65-0P 858521-66-1P
 858521-67-2P 858521-68-3P 858521-69-4P
 858521-70-7P 858521-71-8P 858521-72-9P
 858521-73-0P 858521-74-1P 858521-75-2P
 858521-76-3P 858521-77-4P 858521-78-5P
 858521-79-6P 858521-80-9P 858521-81-0P
 858521-82-1P 858521-83-2P 858521-84-3P
 858521-85-4P 858521-86-5P 858521-87-6P
 858521-88-7P 858521-89-8P 858521-90-1P
 858521-91-2P 858521-92-3P 858521-93-4P
 858521-94-5P 858521-95-6P 858521-96-7P
 858521-99-0P 858522-04-0P 858522-05-1P
 858522-06-2P 858523-09-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 858520-82-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-
 2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858520-95-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopropyl-3-[2-methoxy-4-(1H-pyrazol-
 1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858520-97-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858520-99-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-01-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 858521-02-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1,1-dimethylethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-18-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858521-42-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 858521-51-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2,6-dichlorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-52-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-chloro-6-methylphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 858521-53-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2,6-difluorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 858521-57-0 CAPLUS


CN Benzenesulfonamide, 4-[[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-

dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 858521-58-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 858521-59-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-furanylmethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-60-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 858521-61-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-62-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-
 2,5-dimethyl-N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 858521-63-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-
 2,5-dimethyl-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX
 NAME)




RN 858521-64-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-
 2,5-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 858521-65-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 858521-66-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-67-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-68-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 858521-69-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-70-7 CAPLUS

CN 1-Butanol, 2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 858521-71-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)propyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-72-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 858521-73-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[3-(difluoromethoxy)phenyl]methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-74-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3,4-difluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-75-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-chlorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-76-3 CAPLUS

CN Benzonitrile, 3-chloro-4-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 858521-77-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-chloro-4,6-dimethylphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-78-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-chloro-4,6-dimethoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-79-6 CAPLUS

CN Benzonitrile, 3,5-dichloro-2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 858521-80-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-fluoro-6-(trifluoromethyl)phenyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-81-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 858521-82-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-chloro-4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-83-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-chlorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-84-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[4-(difluoromethoxy)phenyl]methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-85-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3,4-dichlorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-86-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 858521-87-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(5-methyl-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 858521-88-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[5-(2-pyridinyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 858521-89-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 858521-90-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(3-methyl-2-thienyl)methyl]- (9CI) (CA INDEX NAME)




RN 858521-91-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 858521-92-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(2,5-dimethyl-3-furanyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-93-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(5-methyl-3-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)



RN 858521-94-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3,5-dimethyl-4-isoxazolyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 858521-95-6 CAPLUS


CN 1-Butanol, 2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 858521-96-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858521-99-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 858522-04-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[4-(1H-imidazol-1-yl)-2-methoxyphenyl]-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858522-05-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 858522-06-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)propyl]-3-[2-methoxy-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 858523-09-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 858523-42-9P 858523-43-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 858523-42-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-bromo-2-methoxyphenyl)-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 858523-43-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-iodo-2-methoxyphenyl)-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, NH2, (un)substituted alkyl, etc.; R2 = NR5R6 or OR7; R3 = H, alkyl or absent if double bond is present; Y = CO, =(CR4)-; R4 = H, thioalkyl, (un)substituted alkyl, etc.; Ar = (un)substituted Ph or pyridyl; Het = (un)substituted heteroaryl; R5 = H, (un)substituted alkyl, heterocycle, etc.; R6 = (un)substituted alkyl, heterocyclealkyl, aryl, etc.; R7 = (un)substituted alkyl, arylalkyl, heteroarylalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as CRF receptor antagonists. Thus, e.g., II was prepared by cyclization of III (preparation given) with Et acetoacetate followed by chlorination and subsequent substitution with isopropylamine. The CRF receptor binding activity of I was evaluated using radioligand binding assay (no data). I as CRF receptor antagonists should prove useful in the treatment of stroke, depression and anxiety. Pharmaceutical compns. comprising I are disclosed.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:588981 CAPLUS
 DOCUMENT NUMBER: 143:115565
 TITLE: Preparation of tricyclic heterocyclic compound as CRF antagonist
 INVENTOR(S): Nunoya, Kenichi; Matsumura, Naoya; Sugioka, Makiko; Moriguchi, Hideki; Katsumata, Seishi
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061508	A1	20050707	WO 2004-JP19658	20041221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: JP 2003-425778 A 20031222

OTHER SOURCE(S): MARPAT 143:115565

IT 857262-46-5P 857262-47-6P 857262-48-7P

857262-50-1P 857262-51-2P 857262-53-4P


857262-54-5P 857262-55-6P 857262-63-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of cyclopenta[d]pyrazolo[1,5-a]pyrimidine derivs. as CRF 1 antagonist)


RN 857262-46-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-5-methoxy-2-methyl- (9CI)
 (CA INDEX NAME)




RN 857262-47-6 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[2-chloro-4-methoxy-5-(1-methylethoxy)phenyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-48-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-5-ol, 3-(2-chloro-4-methoxyphenyl)-8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-50-1 CAPLUS
 CN 7H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-one, 3-(2-chloro-4-methoxyphenyl)-8-[(1-ethylpropyl)amino]-5,6-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-51-2 CAPLUS
 CN 7H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-one, 3-[2-chloro-4-methoxy-5-(1-methylethoxy)phenyl]-8-[(1-ethylpropyl)amino]-5,6-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-53-4 CAPLUS
 CN 2-Pentanol, 3-[[3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-yl]amino]- (9CI) (CA INDEX NAME)



RN 857262-54-5 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-ethylpropyl]-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-55-6 CAPLUS
 CN 7H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-one, 3-(2-chloro-4-methoxyphenyl)-8-[(1-ethyl-2-oxopropyl)amino]-5,6-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 857262-63-6 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-ol, 3-(2-chloro-4-methoxyphenyl)-8-[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-

ethylpropyl]amino]-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




IT 857262-49-8P 857262-52-3P 857262-56-7P
 857262-57-8P 857262-58-9P 857262-59-0P
 857262-60-3P 857262-61-4P 857262-62-5P
 857262-64-7P 857262-65-8P 857262-66-9P
 857262-71-6P 857262-72-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclopenta[d]pyrazolo[1,5-a]pyrimidine derivs. as CRF 1 antagonist)


RN 857262-49-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-5-one, 3-(2-chloro-4-methoxyphenyl)-8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-52-3 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-ol, 3-(2-chloro-4-methoxyphenyl)-8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-56-7 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-ol, 3-(2-chloro-4-methoxyphenyl)-8-[(1-ethyl-2-hydroxypropyl)amino]-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-57-8 CAPLUS

CN 7H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-one, 3-(2-chloro-5-hydroxy-4-methoxyphenyl)-8-[(1-ethylpropyl)amino]-5,6-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-58-9 CAPLUS

CN 7H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-one, 3-(2-chloro-4-hydroxyphenyl)-8-[(1-ethylpropyl)amino]-5,6-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-59-0 CAPLUS

CN 2-Pentanone, 3-[[3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-yl]amino]- (9CI) (CA INDEX NAME)




RN 857262-60-3 CAPLUS

CN 7H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-one, 3-(2-chloro-4-methoxyphenyl)-8-[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-ethylpropyl]amino]-5,6-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-61-4 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-ol, 3-(2-chloro-5-hydroxy-4-methoxyphenyl)-8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-62-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-ol, 3-(2-chloro-4-hydroxyphenyl)-8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-64-7 CAPLUS

CN 1-Pentanol, 3-[[3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-yl]amino]- (9CI) (CA INDEX NAME)




RN 857262-65-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-7-ol, 3-(2-chloro-4-methoxyphenyl)-8-[(1-ethyl-3-hydroxypropyl)amino]-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 857262-66-9 CAPLUS

CN 2-Pentanone, 3-[[3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-7-hydroxy-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-yl]amino]- (9CI) (CA INDEX NAME)




RN 857262-71-6 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-5-ol, 3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-8-[[1-(hydroxymethyl)propyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 857262-72-7 CAPLUS

CN Phenol, 3-chloro-4-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




IT 441060-02-2

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of cyclopenta[d]pyrazolo[1,5-a]pyrimidine derivs. as CRF 1 antagonist)

RN 441060-02-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



GI




AB Title compds. represented by the formula I [wherein R1, R2 = independently (protected) OH; R3, R = independently (protected) OH or oxo; R4 = R-substituted Et2CH; R5 = (un)oxidized Me; m, n = independently 0-3; and pharmaceutically acceptable salts, solvates, N-oxides, and pro-drugs thereof] were prepared as CRF antagonist. For example, II was given in a 3-step synthesis starting from 4-(2-chloro-4-methoxyphenyl)-3-methyl-1H-pyrazole-5-amine. I were tested for binding activity and antagonistic activity of human CRF 1 with IC50 value of less than 1μM, resp. Thus, I and their pharmaceutical compns. are useful as CRF antagonist for the prevention and/or treatment of psychoneurotic diseases or digestive diseases (no data).


REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:540581 CAPLUS
 DOCUMENT NUMBER: 143:78198
 TITLE: Preparation of pyrazolopyrimidines as antimicrobial agents
 INVENTOR(S): Gebauer, Olaf; Heinemann, Ulrich; Herrmann, Stefan; Gayer, Herbert; Hillebrand, Stefan; Elbe, Hans-Ludwig; Ebbert, Ronald; Wachendorff-Neumann, Ulrike; Dahmen, Peter; Kuck, Karl-Heinz
 PATENT ASSIGNEE(S): Bayer Cropscience Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056555	A1	20050623	WO 2004-EP13930	20041208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10357566	A1	20050707	DE 2003-10357566	20031210
PRIORITY APPLN. INFO.:			DE 2003-10357566	A 20031210
IT 855503-23-0P 855503-39-8P 855503-55-8P RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazolopyrimidines as antimicrobial agents)				
RN 855503-23-0 CAPLUS				
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(4-ethyl-1,3-dioxolan-2-yl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)				




RN 855503-39-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-N-(1,2-dimethylpropyl)-3-(4-ethyl-1,3-dioxolan-2-yl)- (9CI) (CA INDEX NAME)




RN 855503-55-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-fluorophenyl)-3-(4-ethyl-1,3-dioxolan-2-yl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



GI



I




II

AB Title compds. I [R1 = alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl with provisos; R3 = H, halo, alkyl, etc.; R4 = H, alkyl, cycloalkyl, etc.; R5 =

H, alkyl, cycloalkyl, etc.; R6 = H, alkyl, cycloalkyl, etc.; R7 = halo, CN, alkoxy, etc.; R8 = (un)substituted aryl] were prepared For example, sodium borohydride reduction of formylpyrazolopyrimidine II (X = CHO) afforded pyrazolopyrimidine (X = CH₂OH) in 64% yield. In botrytis cinerea inhibition assays, 2-examples of compds. I exhibited over 90% protection at an application rate of 500 g/ha (sic).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:461608 CAPLUS
 DOCUMENT NUMBER: 143:185966
 TITLE: The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists
 AUTHOR(S): Li, Yu-Wen; Fitzgerald, Lawrence; Wong, Harvey; Lelas, Snjezana; Zhang, Ge; Lindner, Mark D.; Wallace, Tanya; McElroy, John; Lodge, Nicholas J.; Gilligan, Paul; Zaczek, Robert
 CORPORATE SOURCE: Neuroscience Biology, Medicinal Chemistry, Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, USA
 SOURCE: CNS Drug Reviews (2005), 11(1), 21-52
 CODEN: CDREFB; ISSN: 1080-563X
 PUBLISHER: Neva Press
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 IT 202579-74-6, DMP904
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmacol. properties suggested that non-peptidergic CRF1 receptor antagonists DMP696 and DMP904 may be effective anxiolytics with low behavioral side effect liabilities in rat model of anxiety)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




AB A review. CRF1 antagonists DMP696 and DMP904 were designed as drug development candidates for the treatment of anxiety and depression. Both compds. display nanomolar affinity for human CRF1 receptors, and exhibit > 1000-fold selectivity for CRF1 over CRF2 receptors and over a broad panel of other proteins. DMP696 and DMP904 block CRF-stimulated adenylyl cyclase activity in cortical homogenates and cell-lines expressing CRF1 receptors. Both compds. inhibit CRF-stimulated ACTH release from rat pituitary corticotropes. Binding and functional studies indicate that DMP696 and DMP904 behave as noncompetitive full antagonists. DMP696 and DMP904 exhibit anxiolytic-like efficacy in several rat anxiety models. In the defensive withdrawal test, both compds. reduce exit latency with lowest EDs of 3 and 1 mg/kg, resp. The anxiolytic-like effect is maintained over 14 days of repeated dosing. In the context of a novel environment used in this test, DMP696 and DMP904 reverse mild stress-induced increases in plasma CORT secretion but at doses 3-4-fold greater than those required for anxiolytic-like efficacy. DMP696 and DMP904 are ineffective in three depression models including the learned helplessness paradigm at doses up to 30 mg/kg. At lowest anxiolytic-like doses, DMP696 and DMP904 occupy >50% CRF1 receptors in the brain. The in vivo IC50 values (plasma concns. required for occupying 50% CRF1

receptors) estimated based upon free, but not total, plasma concns. are an excellent correlation with the in vitro IC50 values. Neither compound produces sedation, ataxia, chlordiazepoxide-like subjective effects or adverse effects on cognition at doses 10-fold higher than anxiolytic-like doses. Neither compound produces physiol. significant changes in cardiovascular, respiratory, gastrointestinal or renal functions at anxiolytic-like doses. DMP696 and DMP904 have favorable pharmacokinetic profiles with good oral bioavailabilities. The overall pharmacol. properties suggest that both compds. may be effective anxiolytics with low behavioral side effect liabilities.

REFERENCE COUNT: 108 THERE ARE 108 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

ACCESSION NUMBER: 2005:268104 CAPLUS
 DOCUMENT NUMBER: 143:19806
 TITLE: Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats
 AUTHOR(S): Wong, Harvey; Lehman-McKeeman, Lois D.; Grubb, Mary F.; Grossman, Scott J.; Bhaskaran, Vasanthi M.; Solon, Eric G.; Shen, Helen S. L.; Gerson, Ronald J.; Car, Bruce D.; Zhao, Bitao; Gemzik, Brian
 CORPORATE SOURCE: Departments of Metabolism and Pharmacokinetics, Discovery Toxicology and Biotransformation, Pharmaceutical Candidate Optimization, 5 Research Parkway, Wallingford, Connecticut, Bristol-Myers Squibb Company, Princeton, NJ, 08543, USA
 SOURCE: Toxicological Sciences (2005), 84(2), 232-242
 CODEN: TOSCF2; ISSN: 1096-6080
 PUBLISHER: Oxford University Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (increased hepatobiliary clearance of unconjugated thyroxine dets. DMP 904-induced alterations in thyroid hormone homeostasis in rats)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




AB 4-(3-Pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (DMP 904) is a potent and selective antagonist of corticotropin releasing factor receptor-1 (CRF1 receptor) with an efficacious anxiolytic profile in preclin. animal models. In subchronic toxicity studies in Sprague-Dawley rats, DMP 904 produced thyroid follicular cell hypertrophy and hyperplasia, and a low incidence of follicular cell adenoma. The current investigations were designed to determine the mode of action by which DMP 904 disrupts thyroid homeostasis in male rats. Five-day treatment with DMP 904 (300 mg/kg/day) dramatically lowered serum thyroxine (T4) to levels below detectable limits (<1 µg/dL) by 72 h, with concurrent decreases in triiodothyronine (T3, about a 70% decrease) and increases in TSH (TSH; about a three-fold increase). DMP 904 increased [125I]T4 total body clearance (Cl_{tb}) (38.21±10.45 mL/h) compared to control (5.61±0.59 mL/h) and phenobarbital-treated rats (7.92±1.62 mL/h). This increase in Cl_{tb} was associated with a significant increase in biliary clearance (Cl_{bile}) of unconjugated [125I]T4 (nearly 80-times control rates) and increased liver:blood ratios of T4, suggestive of enhanced hepatic uptake of T4. A single dose of DMP 904 (200 mg/kg) increased mRNA levels of hepatic

cytochrome P450s (CYP 3A1 and CYP 2B1) and UDP-glucuronosyltransferases (UGT 1A1 and UGT 1A2). DMP 904 also induced mRNAs of the canalicular transporter, multi-drug resistance protein-2 (Mrp2) and sinusoidal transporters, organic anion transporting proteins (Oatp1 and Oatp2) within 24 h. Western blot anal. confirmed DMP 904 related increases in Oatp2 protein expression. Collectively, these data suggest that DMP 904 is an agonist of the constitutive androstane receptor (CAR) and pregnane X receptor (PXR) and that the decreased serum levels of T4 and T3 resulted from increased hepatobiliary clearance. However, DMP 904 is distinguished from other compds. associated with similar effects on thyroid hormone homeostasis because its effects were primarily related to increased biliary excretion of unconjugated T4.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:222553 CAPLUS
 DOCUMENT NUMBER: 142:385821
 TITLE: Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests
 AUTHOR(S): Hogan, John B.; Hodges, Donald B., Jr; Lelas, Snjezana; Gilligan, Paul J.; McElroy, John F.; Lindner, Mark D.
 CORPORATE SOURCE: Neuroscience Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA
 SOURCE: Psychopharmacology (Berlin, Germany) (2005), 178(4), 410-419
 CODEN: PSCHDL; ISSN: 0033-3158
 PUBLISHER: Springer GmbH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP-904
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (CRF1 receptor antagonists and benzodiazepines on cognitive functions)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



AB Benzodiazepines continue to be widely used for the treatment of anxiety, but it is well known that benzodiazepines have undesirable side effects, including sedation, ataxia, cognitive deficits, and the risk of addiction and abuse. CRF1 receptor antagonists are being developed as potential novel anxiolytics, but while CRF1 receptor antagonists seem to have a better side-effect profile than benzodiazepines with respect to sedation and ataxia, the effects of CRF1 receptor antagonists on cognitive function were not well characterized. It is somewhat surprising that the potential cognitive effects of CRF1 receptor antagonists were not more fully characterized since there is some evidence to suggest that these compounds may impair cognitive function. The Morris water maze and the delayed non-matching to position test are sensitive tests of a range of cognitive functions, including spatial learning, attention, and short-term memory, so the objective of the present experiments was to assess the effects of benzodiazepines and CRF1 receptor antagonists in these tests. The benzodiazepines chlordiazepoxide and alprazolam disrupted performance in the Morris water maze and delayed non-matching to position at doses close to their therapeutic, anxiolytic doses. In contrast, the CRF1 receptor antagonists DMP-904 and DMP-696 produced little or no impairment in the Morris water maze or delayed non-matching to position test even at doses 10-fold higher than were necessary to produce anxiolytic effects. The results of the present experiments suggest that, with respect to their effects


on cognitive functions, CRF1 receptor antagonists seem to have a wider therapeutic index than benzodiazepines.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:86349 CAPLUS
DOCUMENT NUMBER: 142:253677
TITLE: Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2
AUTHOR(S): Williamson, Douglas S.; Parratt, Martin J.; Bower, Justin F.; Moore, Jonathan D.; Richardson, Christine M.; Dokurno, Pawel; Cansfield, Andrew D.; Francis, Geraint L.; Hebdon, Richard J.; Howes, Rob; Jackson, Philip S.; Lockie, Andrea M.; Murray, James B.; Nunns, Claire L.; Powles, Jenifer; Robertson, Alan; Surgenor, Allan E.; Torrance, Christopher J.
CORPORATE SOURCE: Granta Park, Vernalis (R&D) Ltd., Cambridge, CB1 6GB, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 863-867
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:253677
IT 771507-72-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-guided design of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors)
RN 771507-72-3 CAPLUS
CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-cyclopentylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 845895-96-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(structure-guided design of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors)
RN 845895-96-7 CAPLUS
CN Benzenesulfonamide, 4-[(5-chloro-3-cyclopentylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




AB The protein structure guided design of a series of pyrazolo[1,5-
 alpyrimidines with high potency for human cyclin-dependent kinase 2 (CDK2)
 is described. Some examples were shown to inhibit the growth of human
 colon tumor cells, were equipotent for CDK1 and were selective against
 GSK-3 β and other kinases.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1154717 CAPLUS
DOCUMENT NUMBER: 142:93846
TITLE: Preparation of pyrazolopyrimidine derivatives as CRF antagonists
INVENTOR(S): Hasegawa, Tomoyuki; Matsui, Toshiaki; Araki, Hiroshi; Saito, Tetsuji; Obitsu, Tetsuo; Okamoto, Masaki; Gemba, Yuichi; Mikami, Yutaka
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113344	A1	20041229	WO 2004-JP9263	20040624
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249629	A1	20041229	AU 2004-249629	20040624
CA 2529561	AA	20041229	CA 2004-2529561	20040624
EP 1637531	A1	20060322	EP 2004-746732	20040624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
NO 2005006093	A	20060324	NO 2005-6093	20051221
PRIORITY APPLN. INFO.:			JP 2003-181908	A 20030625
			WO 2004-JP9263	W 20040624
OTHER SOURCE(S):	MARPAT 142:93846			
IT 817636-92-3P 817636-93-4P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(drug candidate; preparation of pyrazolopyrimidine derivs. as CRF antagonists)				
RN 817636-92-3 CAPLUS				
CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM 1				
CRN 441060-02-2				
CMF C22 H27 Cl N4 O				



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 817636-93-4 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 441060-02-2


CMF C22 H27 Cl N4 O




CM 2

CRN 104-15-4


CMF C7 H8 O3 S



IT 441060-02-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of pyrazolopyrimidine derivs. as CRF antagonists)
 RN 441060-02-2 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-
 methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX
 NAME)



GI



AB The title compds., such as 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxy-phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]-pyrimidine methanesulfonic acid salt (I•MeSO₃H), are prepared as corticotropin-releasing factor (CRF) receptor antagonists. I•MeSO₃H showed antagonistic activity with IC₅₀ of <1 μM against human CRF receptor. Formulations containing I•MeSO₃H as an active ingredient were also described.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:878151 CAPLUS
DOCUMENT NUMBER: 141:366243
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacoopia, Inc.
SOURCE: U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of US Ser. No. 654,546
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209878	A1	20041021	US 2004-776988	20040211
WO 2005077954	A2	20050825	WO 2005-US3859	20050208
WO 2005077954	A3	20051013		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2002-408027P P 20020904
US 2002-421959P P 20021029
US 2003-654546 A2 20030903
US 2004-776988 A 20040211

OTHER SOURCE(S): MARPAT 141:366243


IT 672315-06-9P 672318-10-4P 779353-03-6P
779353-05-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)


RN 672315-06-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-cyclopropyl-5-phenyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 672318-10-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(2-fluorophenyl)-3-phenyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 779353-03-6 CAPLUS

CN 2-Piperidineethanol, 1-[3-cyclopropyl-7-[[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 779353-05-8 CAPLUS

CN Cyclohexanemethanol, 2-[[3-cyclopropyl-7-[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 779353-66-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 779353-66-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-cyclopropyl-N-[(1-oxido-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a


Part

I of I-III series.

L4 ANSWER 17 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857603 CAPLUS
DOCUMENT NUMBER: 141:332189
TITLE: Pyrazolopyrimidine compounds and their use in medicine
INVENTOR(S): Parratt, Martin; Bower, Justin Fairfield; Williamson, Douglas; Cansfield, Andrew
PATENT ASSIGNEE(S): Vernalis Cambridge Limited, UK
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087707	A1	20041014	WO 2004-GB1214	20040318
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1608652	A1	20051228	EP 2004-721593	20040318
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRIORITY APPLN. INFO.:			GB 2003-7389	A 20030331
			GB 2003-12296	A 20030529
			GB 2003-19028	A 20030813
			GB 2003-25854	A 20031105
			WO 2004-GB1214	W 20040318
OTHER SOURCE(S):	MARPAT 141:332189			
IT	771505-38-5P 771505-44-3P 771506-96-8P 771507-07-4P 771507-48-3P 771507-72-3P			
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(drug candidate; preparation of aminopyrazolopyrimidines with kinase inhibitory activity)			
RN	771505-38-5 CAPLUS			
CN	Benzenesulfonamide, 4-[(5-chloro-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)			



RN 771505-44-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771506-96-8 CAPLUS


CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-(3-thienyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771507-07-4 CAPLUS


CN Benzenesulfonamide, 4-[[5-chloro-3-(3-thienyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 771507-48-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.





RN 771507-72-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-cyclopentyl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




GI



AB Compds. of formula (I) or salts, N-oxides, hydrates or solvates thereof are disclosed as inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent C1-C6 alkylene radical; n is 0 or 1. Q represents a radical of formula $-(\text{Alk}1)_p(\text{X})_r-(\text{Alk}2)_s-\text{Z}$ wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring; Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene radicals which may contain a -O-, -S- or -NRA- link, wherein RA is hydrogen or C1-C6 alkyl; X represents -O-, -S-, $-(\text{C}=\text{O})-$, $-(\text{C}=\text{S})-$, $-\text{SO}_2-$, $-\text{SO}-$, $-\text{C}(=\text{O})\text{O}-$, $-\text{OC}(=\text{O})-$, $-\text{C}(=\text{O})\text{NRA}-$, $-\text{NRAC}(=\text{O})-$, $-\text{C}(=\text{S})\text{NRA}-$, $-\text{NRAC}(=\text{S})-$, $-\text{SO}_2\text{NRA}-$, $-\text{NRASO}_2-$, $-\text{OC}(=\text{O})\text{NRA}-$, $-\text{NRAC}(=\text{O})\text{O}-$, or -NRA- wherein RA is hydrogen or C1-C6 alkyl; p, r and s are independently 0 or 1. R1 represents a radical $-(\text{Alk}3)_a-(\text{Y})_b-(\text{Alk}4)_d-\text{B}$ wherein a, b and d are independently 0 or 1; Alk3 and Alk4 are optionally substituted divalent C1-C3 alkylene radicals; Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, -O-, -S-, or -NRA- wherein RA is hydrogen or C1-C6 alkyl; B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is -NRA- and b is 1, then RA and the radical $-(\text{Alk}4)_d-\text{B}$ taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring. R represents H, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, Ph, benzyl, cycloalkyl with 3 to 6 ring atoms, or a monocyclic heterocyclic group having 5 or 6 ring atoms. Preparation of I is also disclosed; thus, e.g., the HCl salt of II was prepared from 5,7-dichloropyrazolo[1,5-a]pyrimidine via substitution with 4-fluoroaniline followed by N-protection with di-*t*-Bu dicarbonate, coupling with Ph boronic acid, and deprotection. I were assayed for CDK2 inhibition and were identified to possess IC₅₀ values ranging from 0.004-24.866 μM . Data for assays of CHK1 kinase activity and PDK dependent kinase activity were given as well as growth inhibition assay data for select example compds.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:750991 CAPLUS
 DOCUMENT NUMBER: 141:271427
 TITLE: Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice
 AUTHOR(S): Nielsen, Darci M.; Carey, Galen J.; Gold, Lisa H.
 CORPORATE SOURCE: Pfizer, Kalamazoo, MI, 49007, USA
 SOURCE: European Journal of Pharmacology (2004), 499(1-2), 135-146
 CODEN: EJPHAZ; ISSN: 0014-2999
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



AB The development of selective corticotropin-releasing factor type-1 (CRF1) receptor antagonists represents a potential novel treatment for depression. These studies evaluated CRF1 receptor antagonists for antidepressant-like activity in mice. Subchronic dosing of both R 121919 (3-[6-(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidin-7-amine) and DMP 696 (4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine) significantly decreased immobility time in the tail suspension test (at 30 and at 3 and 10 mg/kg, i.p., resp.). These antidepressant-like effects were observed at doses that did not impair general locomotor activity. Neither antalarmin (N-butyl-N-ethyl-[2,5,6-trimethyl-7-(2,4,6)trimethylphenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine) nor DMP 904 (4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine) had an effect indicative of antidepressant-like activity. These results suggest that the tail suspension assay may have utility to identify CRF1 receptor antagonists with antidepressant-like activity. Moreover, the results lend support to the theory that some nonpeptidic CRF1 receptor antagonists may possess antidepressant-like activity and therefore represent a promising novel pharmacotherapeutic strategy in the treatment of depression.

REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:740331 CAPLUS
DOCUMENT NUMBER: 141:260763
TITLE: Preparation of pyrazolo[1,5-a]pyrimidines for treating
or preventing protein kinase mediated disorders
INVENTOR(S): Kataoka, Kenichiro; Suzuki, Naotaka; Kosugi, Tomomi;
Imai, Minoru; Makino, Hiroaki; Takakuwa, Mika; Unoki,
Gen; Fujino, Aiko; Oue, Yasuhiro; Yamakoshi, Yuko;
Sugiura, Satoshi; Mitchell, Dale Robert; Simpson,
Donald James; Harris, Clifford John; Le, Joelle
PATENT ASSIGNEE(S): Teijin Pharma Limited, Japan
SOURCE: PCT Int. Appl., 380 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004076458	A1	20040910	WO 2004-JP2522	20040301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004215481	A1	20040910	AU 2004-215481	20040301
CA 2516824	AA	20040910	CA 2004-2516824	20040301
EP 1599482	A1	20051130	EP 2004-716064	20040301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004007834	A	20060214	BR 2004-7834	20040301
CN 1780840	A	20060531	CN 2004-80011183	20040301
NO 2005003955	A	20050922	NO 2005-3955	20050825
PRIORITY APPLN. INFO.:			GB 2003-4665	A 20030228
			US 2003-500695P	P 20030908
			GB 2003-29446	A 20031219
			WO 2004-JP2522	A 20040301

OTHER SOURCE(S): MARPAT 141:260763

IT 754205-87-3P 754206-42-3P 754206-79-6P

754206-80-9P 754208-54-3P 754208-55-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazolo[1,5-a]pyrimidines for treating or preventing
protein kinase mediated disorders)

RN 754205-87-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-(1,3-
dioxan-2-yl)-N7-(4-ethoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754206-42-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-(5,5-dimethyl-1,3-dioxan-2-yl)-N7-(4-ethoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754206-79-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-cyclopropyl-N7-(4-ethoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754206-80-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, 3-cyclopropyl-N7-(4-ethoxyphenyl)-6-methyl-N5-3-piperidinyl- (9CI) (CA INDEX NAME)



RN 754208-54-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-cyclohexyl-N7-(4-ethoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 754208-55-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, 3-cyclohexyl-N7-(4-ethoxyphenyl)-6-

methyl-N5-3-piperidinyl- (9CI) (CA INDEX NAME)



GI



AB The tile compds. [I; R1 = H, alkyl, alkenyl, cycloalkyl, etc.; R2 = H, halo, CN, NO₂, CHO, etc.; R3 = alkyl, cycloalkyl, aryl, etc.; R4 = H, halo, alkyl, cycloalkyl, etc.; R5 = alkyl, alkenyl, cycloalkyl, heterocyclyl, etc.; R6 = H, alkyl, cycloalkyl, aryl, etc.; with the provisos] which exhibit excellent kinase inhibiting activity (particularly MAPKAP-K2 inhibiting activity) and therefore are expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumor growth, were prepared E.g., a multi-step synthesis of II which was active at 1-100 μ M against MAPKAP-K2, was given.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:654772 CAPLUS
DOCUMENT NUMBER: 141:190798
TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives
as cannabinoid receptor ligands
INVENTOR(S): Griffith, David A.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 67 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004157838	A1	20040812	US 2004-762959	20040121
CA 2515596	AA	20040819	CA 2004-2515596	20040128
WO 2004069838	A1	20040819	WO 2004-IB286	20040128
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1594872	A1	20051116	EP 2004-705862	20040128
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007305	A	20060207	BR 2004-7305	20040128
PRIORITY APPLN. INFO.:			US 2003-446450P	P 20030210
			WO 2004-IB286	W 20040128

OTHER SOURCE(S): MARPAT 141:190798


IT 737827-88-2P 737827-89-3P 737827-90-6P
737827-91-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidine derivs. as cannabinoid receptor ligands (antagonists) for treating diseases mediated by cannabinoid receptors)


RN 737827-88-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 737827-89-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 737827-90-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[2-(4-fluorophenyl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 737827-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



GI



AB Compds. of formula (I) [wherein R, R1 = each (un)substituted aryl or heteroaryl; R2, R3 = H, halo, C1-4alkyl, halo-C1-4 alkyl, C1-4 alkoxy; R4 = Q, Q1, OR5 (where R5 taken together with R3 forms a 5- to 6-membered partially saturated heterocyclic ring optionally containing an addnl. oxygen, or a 5-membered heteroaryl, said heterocyclic ring and said heteroaryl being optionally substituted with one or more substituents); R4a = H, C1-3 alkyl; R4b, R4b', R4f, R4f' = H, cyano, HO, NH2, CONH2, C1-6 alkyl, C1-6 alkoxy, acyloxy, acyl, C1-3 alkoxycarbonyl, mono- or di(C1-4 alkyl)carbamoyl, mono- or di(C1-6 alkyl)amino, C3-6 cycloalkylamino, acylamino, aryl(C1-4 alkyl)amino, heteroaryl(C1-4 alkyl)amino, aryl, heteroaryl, each (un)substituted and partially or fully saturated 3-6 membered heterocycle or carbocyclic ring; or either R4b or R4b' taken together with R4e, R4e', R4f, or R4f' forms a bond, a methylene bridge, or an ethylene bridge; X, Z = a bond, (un)substituted CH2CH2; Y = O, S, CO, each (un)substituted CH2CH2 or NH] or pharmaceutically acceptable salt thereof, prodrugs of said compds. or said salts, or solvates or hydrates of said compds., said salts or said prodrugs are prepared These compds. act as

cannabinoid receptor ligands and are useful for treating disease, condition or disorder modulated by a cannabinoid receptor antagonist which is selected from the group consisting of weight loss, obesity, bulimia, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors, alcoholism, tobacco abuse, dementia, seizure disorders, epilepsy, attention deficit disorder, Parkinson's disease, inflammation, gastrointestinal disorders, and type II diabetes. Thus, 1-[2-(2-chlorophenyl)-3-iodopyrazolo[1,5-a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide (90 mg, 0.17 mmol) was coupled with 4-chlorophenylboronic acid (41 mg, 0.26 mmol) in ethanol (2 mL), toluene (2 mL) and 2 M aqueous Na₂CO₃ (1 mL) in the presence of tetrakis(triphenylphosphine)palladium (27 mg, 0.023 mmol) at 80° for 1 h to give 1-[3-(4-Chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide (62 mg, 72%).

L4 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:629705 CAPLUS

DOCUMENT NUMBER: 141:295971

TITLE: Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active

AUTHOR(S): Chen, Chen; Wilcoxon, Keith M.; Huang, Charles Q.; Xie, Yun-Feng; McCarthy, James R.; Webb, Thomas R.; Zhu, Yun-Fei; Saunders, John; Liu, Xin-Jun; Chen, Ta-Kung; Bozigian, Haig; Grigoriadis, Dimitri E.

CORPORATE SOURCE: Neurocrine Biosciences Inc., San Diego, CA, 92121, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(19), 4787-4798

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:295971

IT 195055-53-9P 764651-76-5P 764651-77-6P


764651-78-7P 764651-79-8P 764651-80-1P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, corticotropin-releasing factor receptor activity, and structure-activity relationship of dimethyl(pyridinyl)aminopyrazolopyrimidine derivs.)


RN 195055-53-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 764651-76-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1,2-dimethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 764651-77-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1,4-dimethylpentyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 764651-78-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 764651-79-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 764651-80-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-[(1S)-1-(methoxymethyl)-2-phenylethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI




I


AB It has been shown that 3-phenylpyrazolo[1,5-a]pyrimidines were potent antagonists of the human corticotropin-releasing factor-1 receptor. A series of 3-pyridylpyrazolo[1,5-a]pyrimidines, e.g., I, containing a weakly basic pyridine ring at the 3-position of the bicyclic nucleus was designed to reduce lipophilicity from the initial lead compound. These 3-pyridyl compds. exhibited potent antagonists at the human CRF1 receptor. Moreover, the hydrophilic and weakly basic pyridine moiety increased the water solubility of some analogs. I exhibited good binding affinity at the human CRF1 receptor with a K_i value of 3.5 nM. As a functional antagonist, it dose-dependently inhibited CRF-stimulated cAMP production in cells expressing the CRF1 receptor (IC_{50} = 50 nM), and CRF-stimulated ACTH release from cultured rat pituitary cells (IC_{50} = 20 nM). I had a log P value of 4.9 and water solubility of greater than 10 mg/mL. Pharmacokinetic studies in rats showed that I was orally bioavailable and able to penetrate into the brain. I has been demonstrated in vivo efficacy in animal behavioral models that measure anxiolytic activity. These results suggest that analogs from this series were potent CRF1 receptor antagonists with proper physicochem. properties and good pharmacokinetic profiles. I was developed into a clin. compound and exhibited efficacy in patients with major depression.

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:523288 CAPLUS
 DOCUMENT NUMBER: 141:225452
 TITLE: Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists
 AUTHOR(S): Huang, Charles Q.; Wilcoxon, Keith M.; Grigoriadis, Dimitri E.; McCarthy, James R.; Chen, Chen
 CORPORATE SOURCE: Department of Medicinal Chemistry and Department of Pharmacology, Neurocrine Biosciences, Inc., San Diego, CA, 92129, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(15), 3943-3947
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:225452
 IT 202579-74-6, DMP 904
 RL: PRP (Properties)
 (calculated lipophilicity of corticotropin-releasing factor receptor antagonists)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI



AB A series of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines I [R1 = Cl, O2N, Me, F3C, H2N, HO, etc.; R2 = H, Me, Cl, O2N, H2N, MeO, NO, etc.; R3, R4 = n-Pr, n-Bu, MeOCH2CH2, cyclopropylmethyl, PhCH2] was designed and synthesized as antagonists for the corticotropin-releasing factor-1 (CRF1) receptor. Several compds. such as I [R1 = Me2N; R2 = Me; R3 = R4 = n-Pr; (II)] (Ki = 10 nM) exhibited good binding affinities at the CRF1 receptor. In addition, II had adequate solubility in water.

L4 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:498562 CAPLUS

DOCUMENT NUMBER: 141:207163

TITLE: Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility

AUTHOR(S): Chen, Chen; Wilcoxon, Keith M.; Huang, Charles Q.; McCarthy, James R.; Chen, Takung; Grigoriadis, Dimitri E.

CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3669-3673

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:207163


IT 744222-22-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility)

RN 744222-22-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



GI




I

AB In an effort to identify potent CRF1 antagonists with proper physicochem. properties, a series of 3-phenylpyrazolo[1,5-a]pyrimidines bearing polar groups, such as amino, hydroxyl, methoxy, sulfoxide, were designed and synthesized. Several positions of the core structure were identified, where a polar group was tolerated with slight reduction in receptor binding. NBI 30545 (I) was found to have good binding affinity and potent

antagonistic activity at the human CRF1 receptor. Moreover, this compound had proper lipophilicity ($\log D = 2.78$) and good solubility in water (>10 mg/mL), and exhibited good plasma and brain exposure when given orally.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:292574 CAPLUS
 DOCUMENT NUMBER: 140:368553
 TITLE: Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats
 AUTHOR(S): Lelas, Snjezana; Wong, Harvey; Li, Yu-Wen; Heman, Karen L.; Ward, Kathryn A.; Zeller, Kim L.; Sieracki, Kristine K.; Polino, Joseph L.; Godonis, Helen E.; Ren, Shelly X.; Yan, Xiao-Xin; Arneric, Stephen P.; Robertson, David W.; Hartig, Paul R.; Grossman, Scott; Trainor, George L.; Taub, Rebecca A.; Zaczek, Robert; Gilligan, Paul J.; McElroy, John F.
 CORPORATE SOURCE: Neuroscience Biology, Bristol-Myers Squibb Company, Wallingford, CT, USA
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (2004), 309(1), 293-302
 CODEN: JPETAB; ISSN: 0022-3565
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
 (anxiolytic-like effects of chronic or acute corticotropin-releasing factor1 (CRF1) antagonist DMP904)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



AB Corticotropin-releasing factor1 (CRF1) antagonists may be effective in the treatment of anxiety disorders with fewer side effects compared with classic benzodiazepines. The behavioral effects of DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] and its effects on the hypothalamic-pituitary-adrenal (HPA) axis were related to its levels in plasma and estimated occupancy of central CRF1 receptors. DMP904 (10-30 mg/kg, p.o.) and alprazolam (10 mg/kg, p.o.) increased time spent in open arms of an elevated-plus maze. In addition, acutely or chronically (14 days) administered DMP904 (1.0-30 mg/kg, p.o.) and acute alprazolam (1.0-3.0 mg/kg, p.o.) significantly reduced exit latency in the defensive withdrawal model of anxiety in rats, suggesting that tolerance may not develop to the anxiolytic-like effects of DMP904 in this model of anxiety. Acutely, DMP904 reversed the stress-induced increase in plasma corticosterone levels in defensive

withdrawal at doses of 3.0 mg/kg and higher. These doses also resulted in levels of DMP904 in plasma similar to (for anxiolytic-like effects) or 4-fold higher (for effects on the HPA axis) than the in vitro IC50 value for binding affinity at CRF1 receptors and greater than 50% occupancy of CRF1 receptors. Unlike alprazolam, DMP904 did not produce sedation, ataxia, or chlordiazepoxide-like subjective effects (as measured by locomotor activity, rotorod performance, and chlordiazepoxide discrimination assays, resp.) at doses at least 3-fold higher than anxiolytic-like doses. In conclusion, anxiolytic-like effects and effects on the stress-activated HPA axis of DMP904 in the defensive withdrawal model of anxiety required 50% or greater occupancy of central CRF1 receptors. This level of CRF1 receptor occupancy resulted in fewer motoric side effects compared with classic benzodiazepines.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:269996 CAPLUS
DOCUMENT NUMBER: 140:303691
TITLE: Preparation and pharmaceutical compositions of novel
pyrazolopyrimidines as cyclin dependent kinase
inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;
Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil;
Alvarez, Carmen S.; Chan, Tin-Yau; Knutson, Chad;
Madison, Vincent; Fischmann, Thierry O.; Dillard,
Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray
Anthony; Park, Haengsoon
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacoepia, Inc.
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026229	A2	20040401	WO 2003-US27491	20030903
WO 2004026229	A3	20040617		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497544	AA	20040401	CA 2003-2497544	20030903
AU 2003298571	A1	20040408	AU 2003-298571	20030903
EP 1534712	A2	20050601	EP 2003-796321	20030903
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006502184	T2	20060119	JP 2004-537708	20030903
ZA 2005001846	A	20050912	ZA 2005-1846	20050303
PRIORITY APPLN. INFO.:			US 2002-408029P	P 20020904
			WO 2003-US27491	W 20030903

OTHER SOURCE(S): MARPAT 140:303691


IT 676366-14-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyrazolopyrimidines as cyclin dependent kinase inhibitors)

RN 676366-14-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-cyclopropyl-N-[4-(methylsulfonyl)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



GI



AB In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compds. I [R = (un)substituted aryl; R2 = halo, CN, (un)substituted alkyl, etc.; R3 = H, halo, (un)substituted-alkyl, -alkynyl, -aryl, etc.; R4 = H, halo or alkyl] as inhibitors of cyclin dependent kinases, methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepared by substitution of 3-bromo-7-chloro-5-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidine (preparation given) with aniline. I exhibit excellent CDK inhibitory properties as demonstrated by II which possessed a IC50 value of 0.51 μ M in kinase activity assays.

L4 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:220336 CAPLUS
DOCUMENT NUMBER: 140:270873
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacoepia, Inc.
SOURCE: PCT Int. Appl., 609 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022561	A1	20040318	WO 2003-US27555	20030903
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497440	AA	20040318	CA 2003-2497440	20030903
AU 2003263071	A1	20040329	AU 2003-263071	20030903
EP 1537116	A1	20050608	EP 2003-794592	20030903
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003014001	A	20050705	BR 2003-14001	20030903
JP 2006502163	T2	20060119	JP 2004-534487	20030903
CN 1735614	A	20060215	CN 2003-824997	20030903
NO 2005001647	A	20050603	NO 2005-1647	20050404
PRIORITY APPLN. INFO.:			US 2002-408027P	P 20020904
			US 2002-421959P	P 20021029
			WO 2003-US27555	W 20030903

OTHER SOURCE(S): MARPAT 140:270873


IT 672315-06-9P 672318-10-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)


RN 672315-06-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-cyclopropyl-5-phenyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)






RN 672318-10-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(2-fluorophenyl)-3-phenyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a

Part

I of I-III series.

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:220335 CAPLUS
DOCUMENT NUMBER: 140:270872
TITLE: Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.; Pharmacopeia Drug Discovery, Inc.
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004022560	A1	20040318	WO 2003-US27502	20030903
WO 2004022560	C2	20050707		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497450	AA	20040318	CA 2003-2497450	20030903
AU 2003268385	A1	20040329	AU 2003-268385	20030903
US 2004116442	A1	20040617	US 2003-653868	20030903
EP 1534710	A1	20050601	EP 2003-749347	20030903
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006502161	T2	20060119	JP 2004-534459	20030903
ZA 2005001852	A	20050908	ZA 2005-1852	20050303
PRIORITY APPLN. INFO.:			US 2002-407999P	P 20020904
			WO 2003-US27502	W 20030903

OTHER SOURCE(S): MARPAT 140:270872


IT 673475-04-2P 673475-05-3P 673475-06-4P
673475-07-5P 673475-12-2P 673475-13-3P
673475-17-7P 673475-18-8P 673475-26-8P
673475-27-9P 673475-28-0P 673475-29-1P
673475-30-4P 673475-31-5P 673475-32-6P
673475-33-7P 673475-34-8P 673475-35-9P
673475-36-0P 673475-37-1P 673475-39-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents)


RN 673475-04-2 CAPLUS

CN 4-Pyridinecarboxamide, N-(3-cyclopropyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (9CI) (CA INDEX NAME)




RN 673475-05-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclopropyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (9CI) (CA INDEX NAME)



RN 673475-06-4 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-cyclopropyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 673475-07-5 CAPLUS


CN 4-Pyridinecarboxamide, N-(3-cyclopropyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-

yl)-, 1-oxide (9CI) (CA INDEX NAME)




RN 673475-12-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclopropyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (9CI) (CA INDEX NAME)




RN 673475-13-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(5-chloro-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl)- (9CI) (CA INDEX NAME)




RN 673475-17-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-cyclopropyl-7-[(3-pyridinylcarbonyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 673475-18-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[3-cyclopropyl-7-[(3-pyridinylcarbonyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 673475-26-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(cyclopentylamino)-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673475-27-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(cyclohexylamino)-3-cyclopropylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673475-28-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 673475-29-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673475-30-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 673475-31-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 673475-32-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[2-(hydroxymethyl)-1-piperidinyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673475-33-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[2-(2-hydroxyethyl)-1-piperidinyl]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673475-34-8 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[[1-(hydroxymethyl)cyclopentyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI)
(CA INDEX NAME)



RN 673475-35-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[[(1R,2S)-2-(hydroxymethyl)cyclohexyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 673475-36-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-[[(1R,2R)-2-(hydroxymethyl)cyclohexyl]amino]pyrazolo[1,5-a]pyrimidin-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 673475-37-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-(4-piperidinyloxy)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673475-39-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-cyclopropyl-5-(3-piperidinyloxy)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; Q = SO₂, CO; R = each (un)substituted aryl or heteroaryl; R₂ = cyano, NR₅R₆, CO₂R₆, CONR₅R₆, OR₆, SR₆, SO₂R₇, SO₂NR₅R₆, -N(R₅)SO₂R₇, N(R₅)COR₇, N(R₅)CONR₅R₆, alkynyl, heteroaryl, CF₃, heterocyclyl, alkynylalkyl, cycloalkyl, (un)substituted alkyl; R₃ = H, halogen, NR₅R₆, CONR₅R₆, each (un)substituted alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, etc.; R₄ = H, halo, alkyl; R₅ = H, alkyl; R₆ = H, each (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or R₅ and R₆ in the moiety -NR₅R₆, may be joined together to form an (un)substituted cycloalkyl or heterocyclyl] or pharmaceutically acceptable salts or solvates thereof are prepared. In its many embodiments, the present invention also provides methods of preparing such compds., pharmaceutical compns. containing one or more such compds. I, methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with cyclin dependent kinase using such compds. I or pharmaceutical compns. The disease associated with cyclin dependent kinase is selected from the group consisting of; (1) cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; (2) leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; (3) acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia; (4) fibrosarcoma and rhabdomyosarcoma; (5) astrocytoma, neuroblastoma, glioma and schwannomas; and (6) melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:220334 CAPLUS
DOCUMENT NUMBER: 140:270871
TITLE: Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004022559	A1	20040318	WO 2003-US27405	20030903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497444	AA	20040318	CA 2003-2497444	20030903
AU 2003268357	A1	20040329	AU 2003-268357	20030903
EP 1534709	A1	20050601	EP 2003-749317	20030903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501260	T2	20060112	JP 2004-534424	20030903
CN 1738821	A	20060222	CN 2003-824448	20030903
ZA 2005001851	A	20050908	ZA 2005-1851	20050303
PRIORITY APPLN. INFO.:			US 2002-408030P	P 20020904
			WO 2003-US27405	W 20030903

OTHER SOURCE(S): MARPAT 140:270871


IT 674334-56-6P 674334-87-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents for treating diseases, in particular various cancers, associated with cyclin dependent kinase)


RN 674334-56-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-cyclopropyl-5-phenyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 674334-87-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-(2-fluorophenyl)-3-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R = (un)substituted heteroaryl; R2 = (un)substituted alkyl, alkynyl, aryl, heteroaryl, alkynylalkyl, CF3, heterocyclalkyl, alkynylalkyl, cycloalkyl, CO2R4, etc., wherein aryl is optionally substituted; R3 = H, halogen, NR5R6, CO2R4, CONR5R6, each (un)substituted alkyl, alkynyl, cycloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycl, heterocyclalkyl, or heteroaryl, etc.; R4 = H, halo, alkyl; R5 = H, alkyl; R6 = H, each (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, heterocycl, heterocyclalkyl, heteroaryl, or heteroarylalkyl; or R5 and R6 in the moiety -NR5R6, may be joined together

to form an (un)substituted cycloalkyl or heterocyclyl] or pharmaceutically acceptable salts or solvates thereof are prepared. In its many embodiments, the present invention also provides methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with cyclin dependent kinase using such compds. I or pharmaceutical compns. The disease associated with cyclin dependent kinase is selected from the group consisting of; (1) cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; (2) leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; (3) acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia; (4) fibrosarcoma and rhabdomyosarcoma; (5) astrocytoma, neuroblastoma, glioma and schwannomas; and (6) melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:913167 CAPLUS
DOCUMENT NUMBER: 139:381505
TITLE: Preparation of pyrazolopyrimidines for preventing or
treating herpes virus infection
INVENTOR(S): Gudmundsson, Kristjan S.; Johns, Brian A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095455	A2	20031120	WO 2003-US13395	20030430
WO 2003095455	A3	20031224		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003228770	A1	20031111	AU 2003-228770	20030430
EP 1504004	A2	20050209	EP 2003-726540	20030430
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005529919	T2	20051006	JP 2004-503469	20030430
US 2005203106	A1	20050915	US 2004-512916	20041029
PRIORITY APPLN. INFO.:			US 2002-379421P	P 20020510
			WO 2003-US13395	W 20030430

OTHER SOURCE(S): MARPAT 139:381505


IT 625095-79-6P 625095-80-9P 625095-81-0P
625095-82-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazolopyrimidines for preventing or treating herpes virus
infection)


RN 625095-79-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-
pyridinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 625095-80-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 625095-81-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyridinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 625095-82-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




IT 625095-87-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrazolopyrimidines for preventing or treating herpes virus infection)

RN 625095-87-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; p = 1-3; R1 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R2 = aryl, 5-6 membered heterocyclyl or heteroaryl, aryloxy, etc.; R3, R4 = H, halo, alkyl, aryl, etc.; ring A = aryl, 5-10 membered heterocyclyl or heteroaryl; q = 0-5; R5 = halo, alkyl, cycloalkyl, aryl, etc.], useful for the prophylaxis or treatment of a herpes viral infection in an animal, were prepared Thus, coupling 3-bromo-2-phenyl-7-(pyrrolidin-1-

yl)pyrazolo[1,5-a]pyrimidine with 2-fluoropyridin-4-ylboronic acid (preps. given) in the presence of $\text{PdCl}_2(\text{PPh}_3)_2$, Na_2CO_3 and a few drops of H_2O in DMF afforded 32% II which showed IC_{50} of 28 μM against HSV-1. The pharmaceutical compns. containing the compds. I are claimed.

L4 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:875291 CAPLUS
DOCUMENT NUMBER: 139:350751
TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives
as NAD(P)H oxidase inhibitors
INVENTOR(S): Seno, Kaoru; Nishi, Koichi; Matsuo, Yoshiyuki;
Fujishita, Toshio
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 240 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091256	A1	20031106	WO 2003-JP5024	20030418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483306	AA	20031106	CA 2003-2483306	20030418
AU 2003227437	A1	20031110	AU 2003-227437	20030418
EP 1505068	A1	20050209	EP 2003-717663	20030418
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009475	A	20050301	BR 2003-9475	20030418
CN 1662537	A	20050831	CN 2003-814483	20030418
US 2006089362	A1	20060427	US 2005-511840	20050923
PRIORITY APPLN. INFO.:			JP 2002-121519	A 20020423
			WO 2003-JP5024	W 20030418


OTHER SOURCE(S): MARPAT 139:350751

IT 619305-80-5 619306-08-0 619306-32-0


RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

RN 619305-80-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(methylamino)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 619306-08-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(cyclopropylamino)-N-[3-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 619306-32-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-(cyclopentylamino)-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




IT 619304-52-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrazolo[1,5-a]pyrimidine derivs. as NAD(P)H oxidase inhibitors)

RN 619304-52-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5-carboxamide, 3-(3-chlorophenyl)-7-[(4-fluorophenyl)amino]-N-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



GI




I

AB Title compds. I (R1, R2, R3, R4, R5 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, , aryl, heteroaryl, etc.) and their pharmaceutically acceptable salts, useful in the prevention of or treatments for diseases relating to NAD(P)H, are prepared Thus, N-2-cyclohexylphenyl 3-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amide was prepared in several steps from Et 7-chloropyrazolo[1,5-a]pyrimidine-5-carboxylate.

REFERENCE COUNT: 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:262469 CAPLUS
 DOCUMENT NUMBER: 139:173737
 TITLE: Pharmacological characterization of a novel nonpeptide antagonist radioligand, (±)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl)propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors
 AUTHOR(S): Zhang, Ge; Huang, Ning; Li, Yu-Wen; Qi, Xiaoping; Marshall, Anne P.; Yan, Xiao-Xin; Hill, Geraldine; Rominger, Cynthia; Prakash, Shimoga R.; Bakthavatchalam, Rajagopal; Rominger, David H.; Gilligan, Paul J.; Zaczek, Robert
 CORPORATE SOURCE: CNS Diseases Research, Bristol-Myers Squibb
 SOURCE: Pharmaceutical Research Institute, Wilmington, DE, USA
 JOURNAL: Journal of Pharmacology and Experimental Therapeutics (2003), 305(1), 57-69
 CODEN: JPETAB; ISSN: 0022-3565
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: PAC (Pharmacological activity); BIOL (Biological study) (pharmacol. characterization of a novel nonpeptide antagonist radioligand, (±)-N-[2-Me-4-methoxyphenyl]-1-(1-(methoxymethyl)propyl)-6-Me-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



AB The in vitro pharmacol. profile of a novel small mol. corticotropin-releasing factor 1 (CRF1) receptor antagonist, (±)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl)propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine (SN003), and the characteristics of its radioligand ([3H]SN003) are described. SN003 has high affinity and selectivity for CRF1 receptors expressed in rat cortex, pituitary, and recombinant HEK293EBNA (HEK293e) cells with resp. radiolabeled ovine CRF ([125I]oCRF) binding K_i values of 2.5, 7.9, and 6.8 nM. SN003 was shown to be a CRF1 receptor antagonist inasmuch as it inhibited CRF-induced cAMP accumulation in human CRF1HEK293e cells and CRF-stimulated ACTH hormone release from rat pituitary cells without agonist activities. Significant decreases in the B_{max} of [125I]oCRF binding by SN003 suggest that this antagonist is not simply competitive. To further explore the interaction of SN003 with the CRF1 receptors, [3H]SN003 binding to rat cortex and human CRF1HEK293e cell membranes was characterized and shown to be reversible and saturable,


with KD values of 4.8 and 4.6 nM, and Bmax values of 0.142 and 7.42 pmol/mg protein, resp. The association and dissociation rate consts. of [3H]SN003 (k+1 0.292 nM⁻¹ min⁻¹ and k-1 0.992+10⁻² min⁻¹) were also assessed using human CRF1HEK293e cell membranes, giving an equilibrium dissociation constant of 3.4 nM. Moreover, [3H]SN003 binding displayed a single affinity state and insensitivity to 5'-guanylylimidodiphosphate, consistent with characteristics of antagonist binding. Incomplete inhibition of [3H]SN003 binding by CRF peptides also suggests that SN003 is not simply competitive with CRF at CRF1 receptors. The distribution of [3H]SN003 binding sites was consistent with the expression pattern of CRF1 receptors in rat brain regions. Small mol. CRF1 antagonist radioligands like [3H]SN003 should enable a better understanding of small mol. interactions with the CRF1 receptor.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2002:716091 CAPLUS
 DOCUMENT NUMBER: 137:232665
 TITLE: A process for the preparation of a homochiral corticotropin releasing factor receptor ligand
 INVENTOR(S): Gilligan, Paul J.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072101	A1	20020919	WO 2002-US6834	20020306
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-275331P	P 20010313
OTHER SOURCE(S): CASREACT 137:232665				
IT 457911-55-6P, (-)-7-((R)-Butan-2-ylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (CRF antagonist; process for preparation of a homochiral corticotropin releasing factor receptor ligand)				
RN 457911-55-6 CAPLUS				
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry. Rotation (-).



GI



AB A process for the preparation of corticotropin releasing factor receptor I was disclosed. 2-Methyl-4-methoxybenzyl bromide (prepn given) was converted to the nitrile (DMF/EtOHaq, NaCN) and acetylated (EtOAc, Na^o, reflux) and reacted with hydrazine to give an intermediate pyrazole. This was reacted with Et acetoacetate (HOAc, reflux) to form 7-hydroxy-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine (II). II was treated with POCl₃ (PhMe, DIEA) and the chloride displaced with (R)-2-butylamine to afford I. I is used in treating anxiety, depression, and other psychiatric, neurol. disorders as well as treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:521741 CAPLUS
 DOCUMENT NUMBER: 137:93768
 TITLE: Preparation of tricyclic heterocyclic derivative
 compounds as antagonists of corticotropin release
 factor receptor and drugs containing these compounds
 as the active ingredient
 INVENTOR(S): Nakai, Hisao; Kagamiishi, Yoshifumi
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 456 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053565	A1	20020711	WO 2001-JP11581	20011227
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2432148	AA	20020711	CA 2001-2432148	20011227
EP 1354884	A1	20031022	EP 2001-995808	20011227
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CN 1491225	A	20040421	CN 2001-822720	20011227
JP 3528968	B2	20040524	JP 2002-555088	20011227
BR 2001016609	A	20050215	BR 2001-16609	20011227
NZ 526712	A	20050324	NZ 2001-526712	20011227
NO 2003002956	A	20030828	NO 2003-2956	20030626
ZA 2003005003	A	20050527	ZA 2003-5003	20030626
US 2004072833	A1	20040415	US 2003-250328	20030630
US 7034153	B2	20060425		
JP 2004083597	A2	20040318	JP 2003-406938	20031205
US 2006122392	A1	20060608	US 2005-219736	20050907
PRIORITY APPLN. INFO.:			JP 2000-402517	A 20001228
			JP 2002-555088	A3 20011227
			WO 2001-JP11581	W 20011227
			US 2003-250328	A1 20030630

OTHER SOURCE(S): MARPAT 137:93768
 IT 441056-88-8P 441056-91-3P 441056-92-4P
 441056-93-5P 441056-94-6P 441056-96-8P
 441056-97-9P 441057-00-7P 441057-01-8P
 441057-02-9P 441057-03-0P 441057-04-1P
 441057-05-2P 441057-06-3P 441057-07-4P
 441057-08-5P 441057-09-6P 441057-12-1P
 441057-14-3P 441057-15-4P 441057-16-5P
 441057-17-6P 441057-18-7P 441057-19-8P
 441057-20-1P 441057-21-2P 441057-22-3P
 441057-24-5P 441057-25-6P 441057-26-7P
 441057-28-9P 441057-29-0P 441057-30-3P
 441057-31-4P 441057-34-7P 441057-35-8P

441057-37-0P 441057-38-1P 441057-39-2P
 441057-40-5P 441057-41-6P 441057-43-8P
 441057-45-0P 441057-46-1P 441057-47-2P
 441057-48-3P 441057-49-4P 441057-50-7P
 441057-51-8P 441057-53-0P 441057-54-1P
 441057-55-2P 441057-56-3P 441057-57-4P
 441057-58-5P 441057-59-6P 441057-60-9P
 441057-62-1P 441057-63-2P 441057-66-5P
 441057-68-7P 441057-69-8P 441057-70-1P
 441057-71-2P 441057-75-6P 441057-76-7P
 441057-80-3P 441057-81-4P 441057-89-2P
 441057-90-5P 441058-03-3P 441058-17-9P
 441058-20-4P 441058-27-1P 441058-28-2P
 441058-43-1P 441058-46-4P 441058-51-1P
 441058-52-2P 441058-61-3P 441058-64-6P
 441058-87-3P 441058-88-4P 441058-89-5P
 441058-90-8P 441058-97-5P 441058-98-6P
 441058-99-7P 441059-00-3P 441059-02-5P
 441059-03-6P 441059-04-7P 441059-05-8P
 441059-06-9P 441059-07-0P 441059-08-1P
 441059-09-2P 441059-10-5P 441059-11-6P
 441059-12-7P 441059-13-8P 441059-19-4P
 441059-20-7P 441059-24-1P 441059-39-8P
 441059-44-5P 441059-45-6P 441059-52-5P
 441059-63-8P 441059-64-9P 441059-65-0P
 441059-85-4P 441059-95-6P 441059-96-7P
 441059-97-8P 441059-98-9P 441060-02-2P
 441060-03-3P 441060-04-4P 441060-05-5P
 441060-06-6P 441060-07-7P 441060-08-8P
 441060-09-9P 441060-10-2P 441060-17-9P
 441060-19-1P 441060-28-2P 441060-31-7P
 441060-35-1P 441060-37-3P 441060-39-5P
 441060-47-5P 441060-53-3P 441060-61-3P
 441060-62-4P 441060-63-5P 441060-65-7P
 441061-04-7P 441061-05-8P 441061-06-9P
 441061-07-0P 441061-08-1P 441061-10-5P
 441061-12-7P 441061-13-8P 441061-15-0P
 441061-16-1P 441061-17-2P 441061-20-7P
 441061-21-8P 441061-22-9P 441061-23-0P
 441061-25-2P 441061-28-5P 441061-32-1P
 441061-36-5P 441061-39-8P 441061-40-1P
 441061-53-6P 441061-55-8P 441061-70-7P
 441061-74-1P 441061-81-0P 441061-90-1P
 441062-02-8P 441062-05-1P 441062-06-2P
 441062-07-3P 441062-08-4P 441062-09-5P
 441062-10-8P 441062-11-9P 441062-12-0P
 441062-13-1P 441062-14-2P 441062-15-3P
 441062-16-4P 441062-17-5P 441062-19-7P
 441062-20-0P 441062-22-2P 441062-24-4P
 441062-27-7P 441062-28-8P 441062-29-9P
 441062-39-1P 441062-41-5P 441062-42-6P
 441062-44-8P 441062-45-9P 441062-47-1P
 441062-48-2P 441062-50-6P 441062-57-3P
 441062-59-5P 441062-62-0P 441063-79-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of tricyclic heterocyclic derivative compds. as antagonists of
 corticotropin release factor receptor and drugs containing them as active

ingredient)


RN 441056-88-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441056-91-3 CAPLUS

CN 5H,7H-Pyrazolo[1,5-a]thieno[3,4-d]pyrimidin-8-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441056-92-4 CAPLUS

CN Pyrazolo[1,5-a]thieno[3,2-d]pyrimidin-9-amine, N-(1-ethylpropyl)-2,3-dihydro-5-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 441056-93-5 CAPLUS

CN Furo[3,2-d]pyrazolo[1,5-a]pyrimidin-9-amine, N-(1-ethylpropyl)-2,3-dihydro-5-(4-methoxy-2-methylphenyl)-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441056-94-6 CAPLUS
 CN 5H-Pyrano[3,2-d]pyrazolo[1,5-a]pyrimidin-9-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 441056-96-8 CAPLUS
 CN 1H-Pyrazolo[1,5-a]pyrrolo[3,2-d]pyrimidin-9-amine, N-(1-ethylpropyl)-2,3-dihydro-5-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 441056-97-9 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl

RN 441057-00-7 CAPLUS


CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 441057-01-8 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-[(1S)-1-(dimethoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 441057-02-9 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-[(1S)-1-(dimethoxymethyl)propyl]-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 441057-03-0 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 441057-04-1 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-[3-methoxy-1-(2-methoxyethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-05-2 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-06-3 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-N-[3-methoxy-1-(2-methoxyethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI)
(CA INDEX NAME)



RN 441057-07-4 CAPLUS


CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441057-08-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-09-6 CAPLUS

CN 5H-Pyrazolo[1,5-a]pyrrolo[3,4-d]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-12-1 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(dicyclopropylmethyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-14-3 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-2-(methoxymethyl)-3-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 441057-15-4 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(1,3-benzodioxol-5-yl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-16-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(3,4-dimethoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 441057-17-6 CAPLUS


CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-cyclopropyl-3-(4-methoxy-3-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 441057-18-7 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 2-cyclobutyl-N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-3-methylphenyl)- (9CI) (CA INDEX NAME)

NAME)




RN 441057-19-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 2-ethyl-N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 441057-20-1 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-3-methylphenyl)-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441057-21-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(2-ethylbutyl)-6,7-dihydro-3-(4-methoxy-3-methylphenyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441057-22-3 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-3-methylphenyl)-2-(methylthio)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441057-24-5 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-3-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-25-6 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,5-dimethylphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 441057-26-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-cyclobutyl-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-28-9 CAPLUS
 CN 1,3-Propanediol, 2-[[6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-yl]amino]- (9CI) (CA INDEX NAME)



RN 441057-29-0 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-2-(2-furanyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 441057-30-3 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-phenyl-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 441057-31-4 CAPLUS
 CN 1,2-Ethanediamine, N'-[6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-yl]-N,N-dimethyl- (9CI)
 (CA INDEX NAME)




RN 441057-34-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylbutyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl


RN 441057-35-8 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 441057-37-0 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-N-[(1R)-1-(methoxymethyl)propyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 441057-38-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-N-[(1S)-1-(methoxymethyl)propyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 441057-39-2 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-cyclopentyl-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-40-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,4-difluorophenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 441057-41-6 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441057-43-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-cyclohexyl-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-45-0 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-46-1 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxyphenyl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 441057-47-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1,1-dimethylethyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-48-3 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(2,4,6-trimethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441057-49-4 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-cyclobutylethyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441057-50-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 441057-51-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 441057-53-0 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 441057-54-1 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(4-methoxy-2-methylphenyl)-N-[(1R)-1-(methoxymethyl)propyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 441057-55-2 CAPLUS
 CN Furo[3,2-d]pyrazolo[1,5-a]pyrimidin-9-amine, 2,3-dihydro-5-(4-methoxy-2-methylphenyl)-N-[(1R)-1-(methoxymethyl)propyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 441057-56-3 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2,6-dimethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441057-57-4 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(2-methoxy-4,6-dimethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 441057-58-5 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2,6-dimethylphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 441057-59-6 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(2-methoxy-4,6-dimethylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441057-60-9 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethyl-1-methylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441057-62-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[2-chloro-4-(trifluoromethoxy)phenyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441057-63-2 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-

methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 441057-66-5 CAPLUS
CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(2-methoxy-4,5-dimethylphenyl)-2-methyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 441057-68-7 CAPLUS
CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 441057-69-8 CAPLUS
CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 441057-70-1 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 441057-71-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 441057-75-6 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[4-(dimethylamino)-2-methylphenyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 441057-76-7 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-phenylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 441057-80-3 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-[1-(phenylmethyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 441057-81-4 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethyl-4-phenylbutyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 441057-89-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 441057-90-5 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-6,7-dihydro-N-[(1S)-1-(methoxymethyl)-2-phenylethyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 441058-03-3 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-butylpentyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 441058-17-9 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-2-methyl-N-(1-propylbutyl)-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 441058-20-4 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-2-butynyl-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441058-27-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-ethoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441058-28-2 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-ethoxyphenyl)-N-(1-ethylpropyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441058-43-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 441058-46-4 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-2-methyl-N-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 441058-51-1 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(dicyclopropylmethyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441058-52-2 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(dicyclopropylmethyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 441058-61-3 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(3,5-dichloro-2-pyridinyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441058-64-6 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441058-87-3 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-2-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 441058-88-4 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-2-methyl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 441058-89-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-2-methyl-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 441058-90-8 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-[4-methoxy-2-(methylthio)phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 441058-97-5 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-3-(4-fluoro-2-methylphenyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441058-98-6 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,5-dichlorophenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441058-99-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,4-dimethoxyphenyl)-
 N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA
 INDEX NAME)




● HCl

RN 441059-00-3 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-3-(2-
 fluoro-4-methylphenyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA
 INDEX NAME)




● HCl

RN 441059-02-5 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1,2-dimethylpropyl)-
 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 441059-03-6 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-cyclohexylethyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441059-04-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441059-05-8 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-methylpentyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441059-06-9 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-N-(2-methoxy-1-methylethyl)-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441059-07-0 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-methylhexyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441059-08-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 441059-09-2 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441059-10-5 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylhexyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441059-11-6 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441059-12-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(2-methoxyphenyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441059-13-8 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(dicyclopropylmethyl)-3-(4-methoxy-2-methylphenyl)-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 441059-19-4 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-[2-methoxy-5-(1-methylethyl)phenyl]-2-methyl-N-(1-methylpropyl)-, monohydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 441059-20-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(5-fluoro-2-methoxyphenyl)-6,7-dihydro-2-methyl-N-(1-methylpropyl)-, monohydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 441059-24-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(5-chloro-2-methoxyphenyl)-6,7-dihydro-2-methyl-N-(1-methylpropyl)-, monohydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 441059-39-8 CAPLUS
 CN Benzonitrile, 4-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441059-44-5 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-2-methyl-3-[4-(methylthio)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 441059-45-6 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[4-(dimethylamino)phenyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-,


monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 441059-52-5 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[2-chloro-4-(methylthio)phenyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441059-63-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(4-bromo-2-chlorophenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441059-64-9 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,5-dichloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441059-65-0 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,5-dichloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 441059-85-4 CAPLUS


CN Benzoic acid, 3-chloro-4-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441059-95-6 CAPLUS

CN Benzamide, 3-chloro-4-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 441059-96-7 CAPLUS

CN Benzamide, 3-chloro-4-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 441059-97-8 CAPLUS

CN Benzamide, 3-chloro-4-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 441059-98-9 CAPLUS


CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-3-(4-methoxy-2,6-dimethylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441060-02-2 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 441060-03-3 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4,6-dimethoxyphenyl)-N-(1-ethylpropyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441060-04-4 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(4-amino-2-chlorophenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441060-05-5 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 441060-06-6 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[2-chloro-4-(methylamino)phenyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441060-07-7 CAPLUS

CN Benzaldehyde, 2-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 441060-08-8 CAPLUS

CN Benzonitrile, 2-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 441060-09-9 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-ethyl-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 441060-10-2 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-N-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 441060-17-9 CAPLUS


CN Benzoic acid, 2-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-5-methoxy-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441060-19-1 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 441060-28-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(dicyclopropylmethyl)-6,7-dihydro- (9CI) (CA INDEX NAME)




RN 441060-31-7 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(dicyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 441060-35-1 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro- (9CI) (CA INDEX NAME)




RN 441060-37-3 CAPLUS

CN Benzenemethanol, 2-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-5-methoxy- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 441060-39-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(6-methoxy-4-methyl-3-pyridinyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441060-47-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2,6-dimethylphenyl)-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 441060-53-3 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(dicyclopropylmethyl)-6,7-dihydro-3-(4-methoxy-2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 441060-61-3 CAPLUS

CN Butanal, 2-[[6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-yl]amino]-, O-methyloxime, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 441060-62-4 CAPLUS

CN Butanal, 2-[[3-(4-methoxy-2-methylphenyl)-2-methyl-5H,7H-furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-yl]amino]-, O-methyloxime, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 441060-63-5 CAPLUS


CN Butanenitrile, 2-[[6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441060-65-7 CAPLUS

CN Furo[3,2-d]pyrazolo[1,5-a]pyrimidin-9-amine, N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 441061-04-7 CAPLUS

CN 5H-Pyrano[3,2-d]pyrazolo[1,5-a]pyrimidin-9-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441061-05-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-3-methylphenyl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 441061-06-9 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(2-ethylbutyl)-6,7-dihydro-3-(4-methoxy-3-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441061-07-0 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-3-methylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 441061-08-1 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,5-dimethylphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 441061-10-5 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-

dihydro-3-(4-methoxy-2-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 441061-12-7 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylbutyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 441061-13-8 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 441061-15-0 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-N-[(1R)-1-(methoxymethyl)propyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441061-16-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-N-[(1S)-1-(methoxymethyl)propyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441061-17-2 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441061-20-7 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 441061-21-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-cyclobutylethyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 441061-22-9 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(4-methoxy-2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 441061-23-0 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(2-methoxy-4,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 441061-25-2 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethyl-1-methylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI)
 (CA INDEX NAME)



RN 441061-28-5 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[2-chloro-4-(trifluoromethoxy)phenyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI)
 (CA INDEX NAME)




RN 441061-32-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(2-methoxy-4,5-dimethylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441061-36-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 441061-39-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-[1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)




RN 441061-40-1 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethyl-4-phenylbutyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 441061-53-6 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 441061-55-8 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-6,7-dihydro-N-[(1S)-1-(methoxymethyl)-2-phenylethyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441061-70-7 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-butylpentyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441061-74-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-2-methyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 441061-81-0 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-ethoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441061-90-1 CAPLUS
 CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-02-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-[4-methoxy-2-(methylthio)phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-05-1 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-3-(4-fluoro-2-methylphenyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-06-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,5-dichlorophenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-07-3 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-08-4 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-3-(2-fluoro-4-methylphenyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-09-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1,2-dimethylpropyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-10-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-cyclohexylethyl)-6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-11-9 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-methylbutyl)- (9CI) (CA INDEX NAME)




RN 441062-12-0 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-methylpentyl)- (9CI) (CA INDEX NAME)




RN 441062-13-1 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-N-(2-methoxy-1-methylethyl)-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-14-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-(4-methoxy-2-methylphenyl)-2-methyl-N-(1-methylhexyl)- (9CI) (CA INDEX NAME)




RN 441062-15-3 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylhexyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-16-4 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-17-5 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-3-(2-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-19-7 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 6,7-dihydro-3-[2-methoxy-5-(1-methylethyl)phenyl]-2-methyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 441062-20-0 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(5-fluoro-2-methoxyphenyl)-6,7-dihydro-2-methyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 441062-22-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(5-chloro-2-methoxyphenyl)-6,7-dihydro-2-methyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 441062-24-4 CAPLUS

CN Benzonitrile, 4-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 441062-27-7 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-6,7-dihydro-2-methyl-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 441062-28-8 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[4-(dimethylamino)phenyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-29-9 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-[2-chloro-4-(methylthio)phenyl]-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 441062-39-1 CAPLUS


CN Benzoic acid, 3-chloro-4-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441062-41-5 CAPLUS


CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-

methoxyphenyl)-6,7-dihydro-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 441062-42-6 CAPLUS

CN Benzoic acid, 2-[8-[(1-ethylpropyl)amino]-6,7-dihydro-2-methyl-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-3-yl]-5-methoxy-, methyl ester (9CI)
(CA INDEX NAME)




RN 441062-44-8 CAPLUS

CN Furo[3,2-d]pyrazolo[1,5-a]pyrimidin-9-amine, N-(1-ethylpropyl)-2,3-dihydro-5-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 441062-45-9 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 441062-47-1 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(4-methoxy-2-methylphenyl)-N-[(1R)-1-(methoxymethyl)propyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441062-48-2 CAPLUS
 CN Furo[3,2-d]pyrazolo[1,5-a]pyrimidin-9-amine, 2,3-dihydro-5-(4-methoxy-2-methylphenyl)-N-[(1R)-1-(methoxymethyl)propyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441062-50-6 CAPLUS
 CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-

ethoxyphenyl)-N-(1-ethylpropyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-57-3 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-2-methyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 441062-59-5 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441062-62-0 CAPLUS

CN 5H,7H-Furo[3,4-d]pyrazolo[1,5-a]pyrimidin-8-amine, N-(dicyclopropylmethyl)-3-(4-methoxy-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 441063-79-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(6-chloro-1,3-benzodioxol-5-yl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (9CI) (CA INDEX NAME)



GI



AB Tricyclic heterocyclic derivs. such as 6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, 5,7-dihydrofuro[3,4-d]pyrazolo[1,5-a]pyrimidine, and 6,7-dihydro-5H-cyclopenta[e]pyrrolo[2,3-b]pyridine derivs. represented by the following general formula (I) and pharmaceutically acceptable salts thereof [wherein X, Y = C or N, provided that both X and Y are not simultaneously N; W = C, N; U, Z = (un)substituted CH or NH, N, O, S, CO, C(:S); ring A = optionally substituted C4-6 carbocyclic ring or 4 to 5-membered heterocyclic ring possessing at least one of N, O, and S atom; R1 = (un)substituted C1-8 alkyl, C2-8 alkynyl, C2-8 alkenyl, NH2, or OH, SH, S(O)_nR7, etc. (wherein n = 0-2; R7 = C1-8 alkyl, optionally substituted C3-10 bicyclic carbocyclyl, 3- to 10-membered ring bicyclic heterocyclyl, mono or bicyclic heterocyclyl-C1-4 alkyl, mono or bicyclic heterocyclyl-C1-4 alkyl, etc.); R3 = 5 to 10-membered mono or bicyclic heterocyclyl containing

1-4 N, 1 or 2 O and/or 1 or 2 O S atoms substituted by 1-5 groups selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, halo, etc.] or pharmacol. acceptable salts thereof or hydrates thereof are prepared. Because of having a corticotropin release factor (CRF) receptor antagonism, the compds. I are useful in preventing and/or treating diseases caused by unusual secretion of corticotropin release factor, including depression (single episode, recurrent, post-delivery, or child abuse-induced depression), anxiety, anxiety disorders (panic disorder, specific phobia, acrophobia, social phobia, or obsessive-compulsive disorder), emotional disorder, bipolar disorder, post-traumatic stress, digestive ulcer, diarrhea, constipation, irritable bowel syndrome, inflammatory bowel diseases (ulcerous colitis or Crohn's disease), gastrointestinal function disorder accompanied by stress, neurol. vomiting, eating disorder [neurol. anorexia (anorexia nervosa) or overeating], obesity, stress-induced sleep disorder, fibromuscular pain-induced sleep disorder, stress-induced immunosuppression, stress-induced headache, stress-induced fever, stress-induced pain, operation invasion stress, chronic articular rheumatism, osteoarthritis, osteoporosis, psoriasis, and thyroid gland malfunction syndrome. The above diseases also include uveitis, asthma, diseases based on inappropriate antidiarrheic hormone, pain, inflammation, allergy, head trauma, spinal cord injury, ischemic neuron damage, Cushing's disease, seizure (attack), spasm, muscle spasm, epileptic ischemia, Parkinson's disease, Huntington's disease, urinary incontinence, Alzheimer's disease, Alzheimer-type senile dementia, multi-infarction dementia, amyotrophic lateral sclerosis, hypoglycemia, cardiovascular or cardiac diseases (hypertension, tachycardia, or ischemic heart failure), and alc. or drug withdrawal. Thus, a mixture of 150 mg 8-chloro-2-methyl-3-(2-methyl-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and 0.60 mL 3-pentylamine was heated at 140° for 1 h to give 8-(3-pentylamino)-2-methyl-3-(2-methyl-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine (II). The compds. I inhibited the binding of 125I-CRF to human CRF receptor with IC50 of <1 μM. A tablet and an ampule formulation containing II were prepared.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:184863 CAPLUS

DOCUMENT NUMBER: 136:221516

TITLE: Hair growth stimulants containing CRF1 receptor antagonists

INVENTOR(S): Ikeda, Akiko; Okuyama, Shigeru; Shibasaki, Tamotsu; Kawana, Seiji; Kaneko, Katsumi

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019975	A1	20020314	WO 2001-JP7537	20010831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001084417	A5	20020322	AU 2001-84417	20010831
PRIORITY APPLN. INFO.:			JP 2000-269291	A 20000905
			WO 2001-JP7537	W 20010831


OTHER SOURCE(S): MARPAT 136:221516

IT 202579-74-6

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(hair growth stimulants containing CRF1 receptor antagonists)

RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



AB Disclosed are hair growth stimulants containing a corticotropin release factor (CRF) 1 receptor antagonist as the active ingredient. A CRF1 receptor antagonist 2-[N-(2-methylthio-4-isopropylphenyl)-N-ethylamino]-4-[4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridine-1-yl]-6-methylpyrimidine showed keratinocyte cell proliferation promoting effect in cultured human epidermal keratinocyte cells.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:813420 CAPLUS
 DOCUMENT NUMBER: 135:344507
 TITLE: Preparation of azolotriazines and -pyrimidines as
 corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis,
 Argyrios Georgios
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
 SOURCE: U.S., 57 pp., Cont.-in-part of U.S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6313124	B1	20011106	US 1998-14734	19980128
CA 2532925	AA	19980129	CA 1997-2532925	19970723
US 6124289	A	20000926	US 1997-899242	19970723
ZA 9706603	A	19990125	ZA 1997-6603	19970724
US 6136809	A	20001024	US 1998-14999	19980128
LT 4680	B	20000725	LT 1999-8	19990125
CA 2314613	AA	19990805	CA 1999-2314613	19990128
WO 9938868	A1	19990805	WO 1999-US1824	19990128
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9924787	A1	19990816	AU 1999-24787	19990128
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128
JP 2002501922	T2	20020122	JP 2000-529335	19990128
NZ 505079	A	20030829	NZ 1999-505079	19990128
EP 1344779	A1	20030917	EP 2003-75887	19990128
EP 1344779	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 264860	E	20040515	AT 1999-904382	19990128
PT 1049699	T	20040831	PT 1999-904382	19990128
CN 1542010	A	20041103	CN 2003-10122546	19990128
ES 2218991	T3	20041116	ES 1999-904382	19990128
SG 111076	A1	20050530	SG 2002-200204556	19990128
AT 301657	E	20050815	AT 2003-75887	19990128
PT 1344779	T	20051031	PT 2003-75887	19990128
ES 2247478	T3	20060301	ES 2003-75887	19990128
TW 520372	B	20030211	TW 1999-88102636	19990223
US 2003008885	A1	20030109	US 2001-930782	20010816
HK 1060348	A1	20051021	HK 2004-101985	20040317
JP 2005097257	A2	20050414	JP 2004-216483	20040723
PRIORITY APPLN. INFO.:				US 1996-23290P P 19960724
				US 1997-899242 A2 19970723
				US 1996-686047 A 19960724
				CA 1997-2259583 A3 19970723
				JP 1998-507233 A3 19970723

US 1998-14734	A	19980128
US 1998-15001	A	19980128
US 1998-15002	A	19980128
EP 1999-904382	A3	19990128
WO 1999-US1824	W	19990128


OTHER SOURCE(S): MARPAT 135:344507

IT 202579-57-5P 202579-60-0P 202579-62-2P
 202579-63-3P 202579-64-4P 202579-65-5P
 202579-69-9P 202579-73-5P 202579-74-6P
 202579-75-7P 202579-77-9P 202579-78-0P
 202579-80-4P 202579-81-5P 202579-82-6P
 202579-84-8P 202579-87-1P 202579-91-7P
 202579-92-8P 202579-94-0P 202579-95-1P
 202580-25-4P 202580-26-5P 202580-28-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-65-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-69-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-75-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-78-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-82-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-87-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)





RN 202580-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI




AB The title compds. [I or II; A = N, CR; Z = N, CR2; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, alkyl, alkenyl, etc.; R1 = H, alkyl, alkenyl, etc.; R2 = H, alkyl, alkenyl, etc.; R3 = H, SH, OH, etc.; R14 =

C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists (no data) which are useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POCl₃ and N,N-dimethylaniline, followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxy-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R₁ = Me; R₃ = NHCH(CH₂OMe)₂; Ar = 2,4-Cl₂C₆H₃].


REFERENCE COUNT: 103 THERE ARE 103 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

ACCESSION NUMBER: 2001:796238 CAPLUS
 DOCUMENT NUMBER: 135:339292
 TITLE: Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
 INVENTOR(S): Fossa, Anthony A.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 58 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1149583	A2	20011031	EP 2001-303033	20010330
EP 1149583	A3	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2001001456	A	20011204	BR 2001-1456	20010411
CA 2344089	AA	20011013	CA 2001-2344089	20010412
US 2001041673	A1	20011115	US 2001-834477	20010413
PRIORITY APPLN. INFO.:			US 2000-196698P	P 20000413
OTHER SOURCE(S): MARPAT 135:339292				
IT 202579-62-2 202579-64-4 203924-40-7 203924-41-8				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combinations of corticotropin releasing factor antagonists and growth hormone secretagogues)				
RN 202579-62-2 CAPLUS				
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)				




RN 202579-64-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 203924-40-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 203924-41-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-5-methyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



AB This invention is directed to pharmaceutical compns. comprising corticotropin releasing factor antagonist and growth hormone or growth hormone secretagogues, prodrugs thereof, or pharmaceutically acceptable salts of said compds. or said prodrugs (Markush structures given). The invention is also directed to the use of such compns. in the treatment or prevention of osteoporosis and heart-related diseases (including congestive heart failure) in mammals, particularly humans (no data).

L4 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:516900 CAPLUS

DOCUMENT NUMBER: 135:272933

TITLE: Some reactions with ketene dithioacetals. Part I.
Synthesis of antimicrobial pyrazolo[1,5-a]pyrimidines
via the reaction of ketene dithioacetals and
5-aminopyrazoles

AUTHOR(S): Zaharan, Medhat A.; El-Sharief, Ahmed M. Sh.; El-Gaby,
Mohamed S. A.; Ammar, Yousry A.; El-Said, Usama H.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Al-Azhar
University, Nasr City, Egypt

SOURCE: Farmaco (2001), 56(4), 277-283

CODEN: FRMCE8; ISSN: 0014-827X

PUBLISHER: Elsevier Science S.A.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:272933


IT 364043-51-6P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of antimicrobial pyrazolo[1,5-a]pyrimidines via reaction of
ketene dithioacetals with 5-aminopyrazoles)

RN 364043-51-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carbonitrile, 2,5-diamino-3-(1H-benzimidazol-2-
yl)-7-[(2-ethoxyphenyl)amino]- (9CI) (CA INDEX NAME)



GI



I

AB Pyrazolo[1,5-a]pyrimidines such as I (R = 2-, 4-OEt) were synthesized via
the reaction of ketene dithioacetals and 5-aminopyrazoles. The
antibacterial and antifungal activities of some selected compds. were
reported.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:435078 CAPLUS

DOCUMENT NUMBER: 135:61346

TITLE: Preparation of fused heterotricyclic compounds as antagonists against corticotropin-releasing factor receptor

INVENTOR(S): Hibi, Shigeki; Hoshino, Yoriyhis; Yoshiuchi, Tatsuya; Shin, Kogyoku; Kikuchi, Kouichi; Soejima, Motohiro; Tabata, Mutsuko; Takahashi, Yoshinori; Shibata, Hisashi; Hida, Takayuki; Hirakawa, Tetsuya; Ino, Mitsuhiro

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan; et al.

SOURCE: PCT Int. Appl., 255 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042247	A1	20010614	WO 2000-JP8811	20001213
W: AU, BR, CA, CN, HU, IL, KR, MX, NO, NZ, RU, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
JP 2001233876	A2	20010828	JP 2000-375811	20001211
CA 2394120	AA	20010614	CA 2000-2394120	20001213
AU 2001020235	A5	20010618	AU 2001-20235	20001213
AU 773258	B2	20040520		
EP 1238979	A1	20020911	EP 2000-983479	20001213
EP 1238979	B1	20050302		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1408040	A1	20040414	EP 2003-29058	20001213
EP 1408040	B1	20050727		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
NZ 519241	A	20041224	NZ 2000-519241	20001213
AT 290006	E	20050315	AT 2000-983479	20001213
ES 2234704	T3	20050701	ES 2000-983479	20001213
PT 1238979	T	20050729	PT 2000-983479	20001213
AT 300546	E	20050815	AT 2003-29058	20001213
US 2003078277	A1	20030424	US 2002-148836	20020605
US 6951865	B2	20051004		
US 2005004147	A1	20050106	US 2004-903059	20040802
US 6995163	B2	20060207		
US 2005004159	A1	20050106	US 2004-903387	20040802
US 6927221	B2	20050809		

PRIORITY APPLN. INFO.: JP 1999-352553 A 19991213
EP 2000-983479 A3 20001213
WO 2000-JP8811 W 20001213
US 2002-148836 A3 20020605

OTHER SOURCE(S): MARPAT 135:61346


IT 344291-77-6P 344293-47-6P 344294-07-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of fused heterotricyclic compds. as antagonists against corticotropin-releasing factor receptor for preventives or remedies for CRF and/or CRF receptor-related diseases)


RN 344291-77-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[(1-ethylpropyl)amino]-2,5-dimethyl-3-(2,4,6-trimethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 344293-47-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-acetic acid, 7-[(1-ethylpropyl)amino]-2,5-dimethyl-3-(2,4,6-trimethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 344294-07-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-acetic acid, 7-[(1-ethylpropyl)amino]-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



GI



AB Compds. such as pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine, dipyrazolo[1,5-a:4,3-e]pyrimidine, pyrrolo[3,2-c]quinoline, and pyrrolo[3,2-c][1,7]naphthyridine derivs. represented by general formula [I; A, B, D = N, O, S, (CR₁R₂)_m, CO, CS, (un)substituted NH, SO, SO₂ (wherein m = 0-4; R₁, R₂ = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-8 cycloalkyl, etc.); E, G = N, O, S, (CR₆R₇)_p, CO, CS, (un)substituted NH, SO, SO₂ (wherein R₆, R₇ = H, C1-6 alkyl, optionally C1-4 alkyl-substituted C3-5 cycloalkyl, optionally substituted aryl, or heteroaryl, etc.; p = 0, 1, 2); K, L = C, N; the ring formed by K, E, G, J, and L represents an (un)saturated 5- or 6-membered ring; M = M = H, halo, cyano, (un)substituted C1-6 alkyl, (un)substituted NH, OR₁₃, S(O)_qR₁₄, (un)substituted C2-10 alkenyl or alkynyl, (un)substituted C1-6 alkoxy, C1-6 alkylthio, aryl, or heteroaryl (wherein R₁₃ = H, optionally substituted C1-6 alkyl, C1-4 alkylacyl, optionally substituted aryl-C1-4 alkyl or heteroaryl-C1-4 alkyl, or aryl-heteroaryl; R₁₄ = C1-6 alkyl optionally substituted aryl-C1-4 alkyl, aryl, heteroaryl-C1-4 alkyl, or heteroaryl; q = 0, 1, 2); the solid line accompanied by a dotted line represents a single or a double bond] or pharmacol. acceptable salts thereof or their hydrates, which are also adenylate cyclase inhibitors, are prepared These compds. are useful for the prevention and/treatment of diseases related to corticotropin-releasing factor (CRF) and/or corticotropin-releasing factor receptor. The above diseases include depression, mania, child abuse due to depression, depression after child birth, anxiety, general anxiety, panic disorders, phobia, obsessive-compulsive disorders, post-traumatic-stress disorder, autism, emotional disorders, emotional disturbance, bipolar disorder, , schizophrenia, peptic ulcer, irritable bowel syndrome, ulcerative colitis, Crohn's disease, diarrhea, constipation, intestinal functional abnormality accompanied by stress, neurol. vomiting, Alzheimer's disease, neurodegenerative disease, multiple infarction dementia, and senile dementia, neurol. appetite depression, eating disorders, obesity, diabetes, alc. dependence, drug preference, alc. or drug withdrawal symptom. They also include insomnia, migraine headache, stress headache, muscular stress headache, ischemic nerve disorders, excitatory toxin nerve disorders, stroke, progressive supranuclear paralysis, amyotrophic lateral sclerosis, multiple sclerosis, muscle spasm, chronic fatigue syndrome, neurol. social growth-retardation, epilepsy, head injury, spinal injury, writer's cramp, torticollis spastica, cervicobrachial syndrome, Meniere's syndrome, vegetative dystonia, hair loss, neuropathy, hypertension, cardiovascular disorders, tachycardia, congestive heart attack, hyperpnea syndrome, bronchial asthma, apnea syndrome, sudden infant death syndrome, inflammatory disorders, pain, allergy, impotence, menopausal syndrome, fertilization disorder, sterility, cancer, immune function disorders during HIV infection or caused by stress, hemorrhagic stress, Cushing's disease, thyroid gland function abnormality, meningitis, acromegaly, incontinence, and osteoporosis, etc. Thus, a solution of 7-chloro-6-(2-chloroethyl)-3-mesityl-2,5-dimethylpyrazolo[1,5-a]pyrimidine

and 3-aminopentane in Me Et ketone was refluxed for 1 h to give, after treatment with HCl in Et₂O, 8-(1-ethylpropyl)-3-mesityl-2,5-dimethyl-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine hydrochloride (II). II showed IC₅₀ of 100 nM for inhibiting the binding of [125I]sauvagine to human CRF receptor expressed in HEK 293 cells and showed IC₅₀ of 900 nM against adenylic acid cyclase.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:338070 CAPLUS
 DOCUMENT NUMBER: 134:336224
 TITLE: Use of corticotropin releasing factor (CRF)
 antagonists for treating syndrome X
 INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 55 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097709	A2	20010509	EP 2000-309441	20001026
EP 1097709	A3	20051221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AU 776724	B2	20040916	AU 2000-66695	20001024
ZA 2000006008	A	20020426	ZA 2000-6008	20001026
US 6589947	B1	20030708	US 2000-696822	20001026
CA 2325069	AA	20010429	CA 2000-2325069	20001027
NZ 507825	A	20041126	NZ 2000-507825	20001027
PRIORITY APPLN. INFO.:			US 1999-162340P	P 19991029

OTHER SOURCE(S): MARPAT 134:336224


IT 202579-62-2 202579-64-4 203924-40-7
203924-41-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)


RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 203924-40-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 203924-41-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-5-methyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



AB Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

L4 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:247337 CAPLUS
DOCUMENT NUMBER: 134:280853
TITLE: Preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists
INVENTOR(S): Darrow, James W.; De Lombaert, Stephane; Blum, Charles; Tran, Jennifer; Giangordano, Mark; Griffith, David Andrew; Carpino, Philip Albert
PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023388	A2	20010405	WO 2000-US26885	20000929
WO 2001023388	A3	20011018		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2379633	AA	20010405	CA 2000-2379633	20000929
EP 1218381	A2	20020703	EP 2000-967132	20000929
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
US 6476038	B1	20021105	US 2000-676972	20000929
JP 2003510326	T2	20030318	JP 2001-526540	20000929
BG 106507	A	20021229	BG 2002-106507	20020311
NO 2002001357	A	20020523	NO 2002-1357	20020319
ZA 2002002517	A	20030328	ZA 2002-2517	20020328
PRIORITY APPLN. INFO.:			US 1999-156868P	P 19990930
			WO 2000-US26885	W 20000929


OTHER SOURCE(S): MARPAT 134:280853

IT 332225-19-1P 332225-26-0P 332225-31-7P
332225-45-3P 332225-51-1P 332225-68-0P
332225-74-8P 332225-80-6P 332225-86-2P
332225-92-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists)

RN 332225-19-1 CAPLUS


CN 1,2-Ethanediamine, N-[3-(4-chloro-2,6-dimethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)




RN 332225-26-0 CAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,3-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 332225-31-7 CAPLUS
 CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 332225-45-3 CAPLUS
 CN 1,2-Ethanediamine, N-cyclohexyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332225-51-1 CAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332225-68-0 CAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332225-74-8 CAPLUS

CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-ethynylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332225-80-6 CAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-ethynylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332225-86-2 CAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-[2,6-dichloro-4-(1-cyclopenten-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332225-92-0 CAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-[2,6-dichloro-4-(1-cyclopenten-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




IT 332179-38-1P 332227-43-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and
pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists)
RN 332179-38-1 CAPLUS
CN 1,2-Ethanediamine, N-[3-(4-chloro-2,6-dimethylphenyl)-2,5-
dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 332227-43-7 CAPLUS
 CN Carbamic acid, cyclopentyl[2-[[3-(2,3-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; N, CR14; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; A = (un)substituted (CH2)_m (wherein m = 1-3); B = (un)substituted (CH2)_n (n = 0-3); R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl; R5, R6 = H, alkyl, cycloalkyl, etc.] that are selective modulators of NPY1 receptors, and are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension, were prepared E.g., a multi-step synthesis of the pyrazolo[1,5-a]pyrimidine II was

described. The NPY1 receptor binding affinity for the compds. I, expressed as a K_i , ranges from 0.1 nM to 10 μ M. The compds. I are also useful as probes for the localization of NPY1 receptors and as stds. in assays for NPY1 receptor binding. Compds. I were also tested for CRF1 receptor binding affinity.

L4 ANSWER 41 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:247336 CAPLUS
DOCUMENT NUMBER: 134:280866
TITLE: Preparation of certain alkylene diamine-substituted
pyrazolo[1,5-a]-1,5-pyrimidines and
pyrazolo[1,5-a]-1,3,5-triazines as selective
modulators of NPY1 receptors
INVENTOR(S): Darrow, James W.; De Lombaert, Stephane; Blum,
Charles; Tran, Jennifer; Giangiardano, Mark; Griffith,
David Andrew; Carpino, Philip Albert
PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.; De Lombaert,
Stephane
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023387	A2	20010405	WO 2000-US26887	20000929
WO 2001023387	A3	20020124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2379585	AA	20010405	CA 2000-2379585	20000929
US 6372743	B1	20020416	US 2000-676970	20000929
EP 1218379	A2	20020703	EP 2000-967134	20000929
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003510325	T2	20030318	JP 2001-526539	20000929
US 2003069246	A1	20030410	US 2002-83245	20020225
BG 106506	A	20021229	BG 2002-106506	20020311
NO 2002001356	A	20020523	NO 2002-1356	20020319
ZA 2002002519	A	20031128	ZA 2002-2519	20020328
PRIORITY APPLN. INFO.:			US 1999-156869P	P 19990930
			US 2000-676970	A1 20000929
			WO 2000-US26887	W 20000929


OTHER SOURCE(S): MARPAT 134:280866

IT 332178-43-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)

RN 332178-43-5 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




IT 332178-32-2P 332178-33-3P 332178-34-4P
 332178-35-5P 332178-37-7P 332178-38-8P
 332178-39-9P 332178-40-2P 332178-41-3P
 332178-42-4P 332178-44-6P 332178-45-7P
 332178-46-8P 332178-47-9P 332178-48-0P
 332178-49-1P 332178-50-4P 332178-51-5P
 332178-52-6P 332178-53-7P 332178-54-8P
 332178-55-9P 332178-56-0P 332178-57-1P
 332178-59-3P 332178-60-6P 332178-61-7P
 332178-62-8P 332178-63-9P 332178-64-0P
 332178-65-1P 332178-66-2P 332178-67-3P
 332178-68-4P 332178-69-5P 332178-70-8P
 332178-71-9P 332178-72-0P 332178-74-2P
 332178-76-4P 332178-77-5P 332178-78-6P
 332178-79-7P 332178-82-2P 332178-83-3P
 332178-84-4P 332178-85-5P 332178-86-6P
 332178-87-7P 332178-88-8P 332178-89-9P
 332178-90-2P 332178-91-3P 332178-92-4P
 332178-93-5P 332178-94-6P 332178-95-7P
 332178-96-8P 332178-97-9P 332178-98-0P
 332178-99-1P 332179-00-7P 332179-01-8P
 332179-02-9P 332179-03-0P 332179-04-1P
 332179-05-2P 332179-06-3P 332179-07-4P
 332179-08-5P 332179-09-6P 332179-10-9P
 332179-11-0P 332179-12-1P 332179-13-2P
 332179-14-3P 332179-15-4P 332179-16-5P
 332179-17-6P 332179-18-7P 332179-19-8P
 332179-20-1P 332179-21-2P 332179-22-3P
 332179-23-4P 332179-24-5P 332179-25-6P
 332179-26-7P 332179-27-8P 332179-28-9P
 332179-29-0P 332179-30-3P 332179-31-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)

RN 332178-32-2 CAPLUS


CN 1,2-Ethanediamine, N-[3-(4-chloro-2,6-dimethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 332178-33-3 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-34-4 CAPLUS
CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-35-5 CAPLUS
CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-37-7 CAPLUS
CN Benzoic acid, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]-, methyl ester (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332178-38-8 CAPLUS
CN Benzonitrile, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]-, hydrochloride (9CI)
(CA INDEX NAME)



RN 332178-39-9 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 332178-40-2 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethynylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 332178-41-3 CAPLUS

CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]-, trans- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 332178-42-4 CAPLUS


CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-

dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]-, hydrochloride,
trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332178-44-6 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 332178-45-7 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-propoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 332178-46-8 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-propoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 332178-47-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-N-[(6-methyl-2-piperidiny)methyl]- (9CI) (CA INDEX NAME)




RN 332178-48-0 CAPLUS
 CN 1-Butanol, 2-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 332178-49-1 CAPLUS
 CN 1,4-Cyclohexanediamine, N-[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-N'-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 332178-50-4 CAPLUS
CN 1,4-Cyclohexanediamine, N-[2-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-N'-ethyl- (9CI) (CA INDEX NAME)


CCNc1ccc(cc1)NCCNC2=CN(C)C(=N2)c3cc(Cl)c(Cl)cc3C
$$\text{OMe}$$

Page 303

PAGE 1-A




PAGE 2-A



RN 332178-52-6 CAPLUS
 CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332178-53-7 CAPLUS
 CN 1,2-Propanediol, 3-[[2-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 332178-54-8 CAPLUS
 CN 1,4-Cyclohexanediamine, N-[2-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-N'-(2-methylpropyl)-

(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-55-9 CAPLUS
CN Cyclohexanol, 4-[[2-[[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-
dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-methylethyl]amino]- (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332178-56-0 CAPLUS
 CN Cyclohexanol, 2-[[2-[[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 332178-57-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(4,4,4-trifluorobutyl)- (9CI)
 (CA INDEX NAME)



RN 332178-59-3 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2,2-trifluoroethyl)- (9CI)
 (CA INDEX NAME)




RN 332178-60-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(trifluoromethyl)cyclohexyl]-
 (9CI) (CA INDEX NAME)



RN 332178-61-7 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[4-(trifluoromethyl)cyclohexyl]-
 (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332178-62-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2-difluoroethyl)- (9CI) (CA INDEX NAME)




RN 332178-63-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-fluoro-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 332178-64-0 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-fluorocyclohexyl)- (9CI) (CA INDEX NAME)




RN 332178-65-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 332178-66-2 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 332178-67-3 CAPLUS

CN 1,2-Propanediamine, N1-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 332178-68-4 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2-methyl-3-furanyl)-(9CI) (CA INDEX NAME)




RN 332178-69-5 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 332178-70-8 CAPLUS
 CN Benzonitrile, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 332178-71-9 CAPLUS
 CN Benzenemethanol, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-72-0 CAPLUS
 CN 1,2-Ethanediamine, N-[3-[2,6-dichloro-4-(1-cyclopenten-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332178-74-2 CAPLUS
CN Benzenemethanol, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 332178-76-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2-methyl-3-furanyl)- (9CI) (CA INDEX NAME)




RN 332178-77-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-(1,1-dimethylethyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 332178-78-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI)
 (CA INDEX NAME)




RN 332178-79-7 CAPLUS
 CN 1,2-Ethanediamine, N-3-cyclohexen-1-yl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332178-82-2 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-3-piperidiny)- (9CI) (CA INDEX NAME)



RN 332178-83-3 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(phenylmethyl)-3-pyrrolidiny)- (9CI) (CA INDEX NAME)




RN 332178-84-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 332178-85-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-86-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(phenylmethyl)-4-piperidinyl]-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-87-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-methyl-4-piperidiny)- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-88-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-4-piperidinyloxy) (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-89-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-90-2 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332178-91-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-3-piperidiny)- (9CI)
(CA INDEX NAME)




RN 332178-92-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-4-piperidinyloctyl- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 332178-93-5 CAPLUS
 CN 1,2-Propanediamine, N1-[3-(2,6-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 332178-94-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(3-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-95-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(4-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-96-8 CAPLUS
CN Phenol, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(1-phenyl-3-pyrrolidinyl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 332178-97-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


N#CCCCN1CCCCC1CN2C=CC=CC=C2Cc1nc2c(ncn2C)c3cc(OC)c(Cl)c(Cl)c3

Page 332

PAGE 1-A




PAGE 2-A




RN 332178-99-1 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-00-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-01-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(phenylmethyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-02-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-03-0 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2-methyl-5-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332179-04-1 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,4-dichlorophenyl)-2-methyl-5-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-05-2 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-06-3 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-methoxyphenyl)-2-methyl-5-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-07-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-08-5 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-methoxyphenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-09-6 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-methoxyphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-10-9 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichlorophenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-11-0 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dichlorophenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-12-1 CAPLUS
 CN 1,2-Propanediamine, N1-[3-(2,6-dichlorophenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-13-2 CAPLUS
CN 1,2-Ethanediamine, N-[5-ethyl-2-methyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-14-3 CAPLUS
CN 1,2-Propanediamine, N1-[5-ethyl-2-methyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-15-4 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethynylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-16-5 CAPLUS
 CN 1,2-Ethanediamine, N-[2-methyl-5-propyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-17-6 CAPLUS
 CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-18-7 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dimethylphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-19-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dimethylphenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-20-1 CAPLUS
CN 1,2-Propanediamine, N1-[3-(2,6-dimethylphenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-21-2 CAPLUS
 CN 1,2-Propanediamine, N1-[3-(2,6-dimethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332179-22-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,4-dimethylphenyl)-5-ethyl-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332179-23-4 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,4-dimethylphenyl)-2-methyl-5-propylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332179-24-5 CAPLUS
CN 4-Piperidinamine, 1-acetyl-N-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 332179-25-6 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-26-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(3-ethoxy-4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 332179-27-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 332179-28-9 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 332179-29-0 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-30-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(3-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-31-4 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A




IT 332179-70-1 332179-74-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)
RN 332179-70-1 CAPLUS
CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 332179-74-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




IT 332179-38-1P 332179-42-7P 332179-43-8P
 332179-55-2P 332179-56-3P 332179-57-4P
 332179-58-5P 332179-59-6P 332179-60-9P
 332179-66-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)
 RN 332179-38-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(4-chloro-2,6-dimethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332179-42-7 CAPLUS
 CN Benzeneacetamide, N-[2-[[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-4-methoxy-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-43-8 CAPLUS
 CN Benzeneacetamide, N-[2-[[2,5-dimethyl-3-(2,4,6-trimethylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl]-4-ethoxy-3-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-55-2 CAPLUS
CN Benzoic acid, 3,5-dichloro-4-[7-[[2-[[[(1,1-dimethylethoxy)carbonyl](tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 332179-56-3 CAPLUS
CN Carbamic acid, [2-[[3-(2,6-dichloro-4-cyanophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 332179-57-4 CAPLUS
 CN Carbamic acid, [2-[[3-(2,6-dichloro-4-ethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 332179-58-5 CAPLUS
 CN Carbamic acid, [2-[[3-(2,6-dichloro-4-hydroxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 332179-59-6 CAPLUS
 CN Carbamic acid, [2-[[3-[2,6-dichloro-4-[(methylsulfonyl)oxy]phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A





RN 332179-60-9 CAPLUS

CN Carbamic acid, [2-[[3-[2,6-dichloro-4-[(trimethylsilyl)ethynyl]phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]ethyl](tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 332179-66-5 CAPLUS

CN Phenol, 3,5-dichloro-4-[2,5-dimethyl-7-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]pyrazolo[1,5-a]pyrimidin-3-yl]-, hydrobromide (9CI) (CA INDEX NAME)

[illegible]

Page 373

prepared E.g., a multi-step synthesis of the pyrazolo[1,5-a]pyrimidine II, was described. The NPY1 binding affinity for the compds. I, expressed as a K_i value, ranges from 0.1 nM to 10 μ M. Compds. I are also useful as probes for the localization of NPY1 receptors and as stds. in assays for NPY1 receptor binding. Methods of using the compds. I in receptor localization studies are given.

ACCESSION NUMBER: 2001:185043 CAPLUS
 DOCUMENT NUMBER: 134:217215
 TITLE: Use of CRF antagonists and related compositions for
 modifying circadian rhythm and treatment of depression
 and other conditions
 INVENTOR(S): Chen, Yuhpyng Liang
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 29 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1082960	A2	20010314	EP 2000-307074	20000818
EP 1082960	A3	20020320		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6432989	B1	20020813	US 2000-587007	20000605
EP 1449532	A1	20040825	EP 2004-12293	20000818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2001097889	A2	20010410	JP 2000-251836	20000823
ZA 2000004362	A	20020225	ZA 2000-4362	20000824
CA 2316662	AA	20010227	CA 2000-2316662	20000825
NZ 506562	A	20020927	NZ 2000-506562	20000825
AU 776077	B2	20040826	AU 2000-53644	20000825
US 2002156089	A1	20021024	US 2002-161816	20020604
US 2004082597	A1	20040429	US 2003-676201	20031001
PRIORITY APPLN. INFO.:			US 1999-151183P	P 19990827
			US 2000-587007	A3 20000605
			EP 2000-307074	A3 20000818
			US 2002-161816	A3 20020604


IT 202579-62-2 202579-64-4 203924-40-7
203924-41-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CRF antagonists and related compns. for modifying circadian rhythm and treatment of depression and other conditions, and use with other agents)


RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 203924-40-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 203924-41-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-5-methyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



AB A corticotropin releasing factor (CRF) antagonist is administered to treat disorders that can be treated by altering circadian rhythm, as well as depression (in which a second compound for treating depression is administered, the second compound having an onset of action that is delayed with respect to that of the CRF antagonist). Methods for treating cardiovascular diseases, migraine, non-migraine headaches, and emesis are also disclosed.

L4 ANSWER 43 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:131201 CAPLUS
 DOCUMENT NUMBER: 134:178572
 TITLE: Preparation of azolo triazines and pyrimidines as
 corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis,
 Argyrios Georgios
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Co., USA
 SOURCE: U.S., 90 pp., Cont.-in-part of U. S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6191131	B1	20010220	US 1998-15002	19980128
CA 2532925	AA	19980129	CA 1997-2532925	19970723
US 6124289	A	20000926	US 1997-899242	19970723
ZA 9706603	A	19990125	ZA 1997-6603	19970724
US 6136809	A	20001024	US 1998-14999	19980128
LT 4680	B	20000725	LT 1999-8	19990125
CA 2314613	AA	19990805	CA 1999-2314613	19990128
WO 9938868	A1	19990805	WO 1999-US1824	19990128
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9924787	A1	19990816	AU 1999-24787	19990128
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128
JP 2002501922	T2	20020122	JP 2000-529335	19990128
NZ 505079	A	20030829	NZ 1999-505079	19990128
EP 1344779	A1	20030917	EP 2003-75887	19990128
EP 1344779	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 264860	E	20040515	AT 1999-904382	19990128
PT 1049699	T	20040831	PT 1999-904382	19990128
CN 1542010	A	20041103	CN 2003-10122546	19990128
ES 2218991	T3	20041116	ES 1999-904382	19990128
SG 111076	A1	20050530	SG 2002-200204556	19990128
AT 301657	E	20050815	AT 2003-75887	19990128
PT 1344779	T	20051031	PT 2003-75887	19990128
ES 2247478	T3	20060301	ES 2003-75887	19990128
TW 520372	B	20030211	TW 1999-88102636	19990223
US 6358950	B1	20020319	US 2000-696759	20001026
HK 1060348	A1	20051021	HK 2004-101985	20040317
JP 2005097257	A2	20050414	JP 2004-216483	20040723
PRIORITY APPLN. INFO.:				US 1996-23290P P 19960724
				US 1997-899242 A2 19970723
				US 1996-686047 A 19960724
				CA 1997-2259583 A3 19970723
				JP 1998-507233 A3 19970723

US 1998-14734	A	19980128
US 1998-15001	A	19980128
US 1998-15002	A	19980128
EP 1999-904382	A3	19990128
WO 1999-US1824	W	19990128

OTHER SOURCE(S): MARPAT 134:178572


IT 202579-57-5P 202579-60-0P 202579-62-2P
 202579-63-3P 202579-64-4P 202579-65-5P
 202579-69-9P 202579-73-5P 202579-74-6P
 202579-75-7P 202579-77-9P 202579-78-0P
 202579-80-4P 202579-81-5P 202579-82-6P
 202579-84-8P 202579-87-1P 202579-91-7P
 202579-92-8P 202579-94-0P 202579-95-1P
 202580-25-4P 202580-26-5P 202580-28-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolo-fused triazines and pyrimidines as CRF antagonists)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-65-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-69-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-75-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-78-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-82-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-87-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)





RN 202580-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR2; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, alk(en/yn)yl, halo, etc.; R1, R2 = H, alk(en/yn)yl, halo, etc.; R3 = H, SH, aryl, etc.; R14 = (un)substituted

alk(en/yn)yl, cycloalkyl(alkyl)], useful in treating CRF-related disorders, particularly anxiety, depression, and other psychiatric, neurol. disorders as well as treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. For instance, 5-amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole was cyclized with Et acetoacetate in AcOH to give 42% 7-hydroxy-2,5-dimethyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine. The latter was treated with POCl₃ and PhNEt₂ to give the 7-chloro analog (84%), which reacted with 3-pentylamine to give 60% title compound I [A = CH; R₁ = Me; R₃ = NHCH₂Et; Z = CMe; Ar = 2-Cl-4-MeC₆H₃]. The compds. I are effective at 0.002-200 mg/kg/day.

REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:307132 CAPLUS
 DOCUMENT NUMBER: 132:321873
 TITLE: Azolo triazines and pyrimidines useful as
 corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): Gilligan, Paul; Chorvat, Robert; Arvanitis, Argyrios
 Georgios
 PATENT ASSIGNEE(S): DuPont Pharmaceuticals Co., USA
 SOURCE: U.S., 86 pp., Cont.-in-part of U.S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6060478	A	20000509	US 1998-15001	19980128
CA 2532925	AA	19980129	CA 1997-2532925	19970723
US 6124289	A	20000926	US 1997-899242	19970723
ZA 9706603	A	19990125	ZA 1997-6603	19970724
US 6136809	A	20001024	US 1998-14999	19980128
LT 4680	B	20000725	LT 1999-8	19990125
CA 2314613	AA	19990805	CA 1999-2314613	19990128
WO 9938868	A1	19990805	WO 1999-US1824	19990128
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9924787	A1	19990816	AU 1999-24787	19990128
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128
JP 2002501922	T2	20020122	JP 2000-529335	19990128
NZ 505079	A	20030829	NZ 1999-505079	19990128
EP 1344779	A1	20030917	EP 2003-75887	19990128
EP 1344779	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 264860	E	20040515	AT 1999-904382	19990128
PT 1049699	T	20040831	PT 1999-904382	19990128
CN 1542010	A	20041103	CN 2003-10122546	19990128
ES 2218991	T3	20041116	ES 1999-904382	19990128
SG 111076	A1	20050530	SG 2002-200204556	19990128
AT 301657	E	20050815	AT 2003-75887	19990128
PT 1344779	T	20051031	PT 2003-75887	19990128
ES 2247478	T3	20060301	ES 2003-75887	19990128
TW 520372	B	20030211	TW 1999-88102636	19990223
HK 1060348	A1	20051021	HK 2004-101985	20040317
JP 2005097257	A2	20050414	JP 2004-216483	20040723
PRIORITY APPLN. INFO.:				
			US 1996-23290P	P 19960724
			US 1997-899242	A2 19970723
			US 1996-686047	A 19960724
			CA 1997-2259583	A3 19970723
			JP 1998-507233	A3 19970723
			US 1998-14734	A 19980128

US 1998-15001	A	19980128
US 1998-15002	A	19980128
EP 1999-904382	A3	19990128
WO 1999-US1824	W	19990128

OTHER SOURCE(S): MARPAT 132:321873

IT 202579-57-5P 202579-60-0P 202579-62-2P
 202579-63-3P 202579-64-4P 202579-65-5P
 202579-69-9P 202579-73-5P 202579-74-6P
 202579-75-7P 202579-77-9P 202579-78-0P
 202579-80-4P 202579-81-5P 202579-82-6P
 202579-84-8P 202579-87-1P 202579-91-7P
 202579-92-8P 202579-94-0P 202579-95-1P
 202580-25-4P 202580-26-5P 202580-28-7P
 202580-53-8P 202580-54-9P 202580-56-1P
 202580-57-2P 202580-58-3P 202580-59-4P
 234776-70-6P 234776-71-7P 234776-75-1P
 234776-76-2P 234776-80-8P 234776-81-9P
 234776-82-0P 234776-83-1P 234776-84-2P
 234776-86-4P 234776-87-5P 234776-88-6P
 234776-89-7P 234776-90-0P 234776-93-3P
 234776-94-4P 234776-98-8P 234776-99-9P
 234777-00-5P 234777-01-6P 234777-03-8P
 234777-06-1P 234777-08-3P 234777-11-8P
 234777-12-9P 234777-13-0P 234777-14-1P
 234777-15-2P 234777-16-3P 234777-20-9P
 234777-21-0P 234777-25-4P 234777-26-5P
 234777-27-6P 234777-28-7P 234777-29-8P
 234777-31-2P 234777-32-3P 234777-33-4P
 234777-34-5P 234777-35-6P 234777-38-9P
 234777-39-0P 234777-44-7P 234777-45-8P
 234777-46-9P 234777-47-0P 234777-49-2P
 234777-52-7P 234777-54-9P 234777-57-2P
 234777-58-3P 234777-59-4P 234777-60-7P
 234777-61-8P 234777-62-9P 234777-66-3P
 234777-67-4P 234777-71-0P 234777-72-1P
 234777-73-2P 234777-74-3P 234777-75-4P
 234777-77-6P 234777-78-7P 234777-79-8P
 234777-80-1P 234777-81-2P 234777-84-5P
 234777-85-6P 234777-89-0P 234777-90-3P
 234777-91-4P 234777-92-5P 234777-94-7P
 234777-97-0P 234777-99-2P 234778-02-0P
 234778-03-1P 234778-04-2P 234778-11-1P
 234778-12-2P 234778-19-9P 234778-20-2P
 234778-27-9P 234778-28-0P 234778-35-9P
 234778-36-0P 234778-43-9P 234778-44-0P
 234778-51-9P 234778-52-0P 235083-80-4P
 267233-61-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of azolo-fused triazines and pyrimidines as

CRF

antagonists)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-65-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-69-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-75-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-77-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-78-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-82-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-87-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-53-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 202580-54-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-56-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-57-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-70-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234776-71-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-75-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-76-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-80-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-81-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-82-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI)
 (CA INDEX NAME)




RN 234776-83-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234776-84-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-86-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-87-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234776-88-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-89-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234776-90-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-93-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234776-94-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-

[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-98-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-99-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-00-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-6-chloro-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-01-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-chloro-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-03-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-chloro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-06-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-08-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 234777-11-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-12-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-13-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-14-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-15-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-2,5,6-trimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234777-16-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-20-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-21-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-27-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-28-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-29-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-31-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-32-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-2,5,6-trimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234777-33-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-34-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-35-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-38-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-39-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-44-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-45-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-46-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-47-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-49-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-52-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-54-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-57-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-58-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-59-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-60-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-61-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-62-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-66-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-67-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-71-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-72-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-73-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-74-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 234777-75-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-77-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-78-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234777-79-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-80-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234777-81-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-84-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-85-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-89-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-90-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-91-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-92-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-94-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-97-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-99-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-02-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-6-fluoro-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-03-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-04-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-11-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-12-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-19-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-20-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-27-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-28-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234778-35-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-36-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-43-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-44-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234778-51-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-52-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 235083-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)






RN 267233-61-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI



AB Corticotropin releasing factor (CRF) antagonists (no data) of formulas I and II are disclosed [wherein A = N or CR; Z = N or CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, pyrimidinyl, indanyl, tetralinyl, addnl. selected heterocycles; R = H, alk(en/yn)yl, cycloalkyl(alkyl), halo, cyano, haloalkyl; R₁, R₂ = H, groups listed for R, NH₂ or derivs., OH or derivs., SH or derivs., addnl. substituted alkyls; R₃ = H, OH or derivs., SH or derivs., acyl, CO₂H or esters, NH₂ or derivs., aryl, heteroaryl, alk(en/yn)yl, etc.; R₄ = (un)substituted alk(en/yn)yl or cycloalkyl(alkyl)]. The compds. are of use in the treatment of CRF-related disorders, particularly anxiety and depression, as well as other psychiatric, neurol., immunol., cardiovascular, and psychopathol. disorders. For instance, 5-amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole was cyclized with Et acetoacetate in AcOH to give 42% 7-hydroxy-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine.

The latter was treated with POCl₃ and PhNEt₂ to give the 7-chloro analog (84%), which reacted with 3-pentylamine to give 60% title compound III.

REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2000:125866 CAPLUS

DOCUMENT NUMBER: 132:231516

TITLE: The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist


CORPORATE SOURCE: Chemical and Physical Sciences Department,
Experimental Station, DuPont Pharmaceuticals Co.,
Wilmington, DE, 10880-0500, USA

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: General
LANGUAGE: English


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (structure-activity relationships of pyrazolo-[1,5-a]-pyrimidines as human CRF1 antagonists leading to discovery of anxiolytic DMP904)

CN	Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)
----	--




RN 202579-60-0 CAPLUS

Page 429




RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethoxypropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethoxypropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-28-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 262298-00-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethoxypropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




IT 202579-57-5P 202579-64-4P 202579-65-5P
 202579-69-9P 202579-73-5P 202579-80-4P
 202579-81-5P 202579-82-6P 202579-92-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (structure-activity relationships of pyrazolo-[1,5-a]-pyrimidines as human CRF1 antagonists leading to discovery of anxiolytic DMP904)
 RN 202579-57-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-65-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-69-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-82-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



AB Structure-activity relationship studies led to the discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine (compound 11-31, DMP904), whose pharmacol. profile strongly supports the hypothesis that hCRF1 antagonists may be potent anxiolytic drugs. Compound 11-31 (hCRF1 $K_i = 1.0 \pm 0.2$ nM ($n = 8$)) was a potent antagonist of hCRF1-coupled adenylate cyclase activity in HEK293 cells ($IC_{50} = 10.0 \pm 0.01$ nM vs. 10 nM r/hCRF, $n = 8$); α -helical CRF(9-41) had weaker potency ($IC_{50} = 286 \pm 63$ nM, $n = 3$). Analog 11-31 had good oral activity in the rat situational anxiety test; the min. ED for 11-31 was 0.3 mg/kg, orally. Maximal efficacy (approx. 57% reduction in latency time in the dark compartment) was observed at this dose. Chlordiazepoxide caused a 72% reduction in latency at 20 mg/kg, orally. CP154526-1 (30 mg/kg, orally) was inactive in this test. Compound 11-31 did not inhibit open-field locomotor activity at 10, 30, and 100 mg/kg, orally

in rats. In beagle dogs, this compound (5 mg/kg, i.v., orally) afforded good plasma levels. The key i.v. pharmacokinetic parameters were $t_{1/2}$, CL and $V_{d,ss}$ values equal to 46.4 ± 7.6 h, 0.49 ± 0.08 L/kg/h and 23.0 ± 4.2 L/kg, resp. After oral dosing, the mean C_{max} , T_{max} , $t_{1/2}$ and bioavailability values were equal to 1260 ± 290 nM, 0.75 ± 0.25 h, 45.1 ± 10.2 h and 33.1%, resp. The overall rat behavioral profile of this compound suggests that it may be an anxiolytic drug with a low motor side effect liability.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:495296 CAPLUS
DOCUMENT NUMBER: 131:144616
TITLE: Preparation of azolotriazines and -pyrimidines as
corticotropin releasing factor (CRF) antagonists
INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis,
Argyrios Georgios
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938868	A1	19990805	WO 1999-US1824	19990128
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6060478	A	20000509	US 1998-15001	19980128
US 6191131	B1	20010220	US 1998-15002	19980128
US 6313124	B1	20011106	US 1998-14734	19980128
CA 2314613	AA	19990805	CA 1999-2314613	19990128
AU 9924787	A1	19990816	AU 1999-24787	19990128
AU 748818	B2	20020613		
EP 1049699	A1	20001108	EP 1999-904382	19990128
EP 1049699	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9908206	A	20001205	BR 1999-8206	19990128
JP 2002501922	T2	20020122	JP 2000-529335	19990128
NZ 505079	A	20030829	NZ 1999-505079	19990128
AT 264860	E	20040515	AT 1999-904382	19990128
ZA 9900843	A	20000802	ZA 1999-843	19990203
PRIORITY APPLN. INFO.:			US 1998-14734	A 19980128
			US 1998-15001	A 19980128
			US 1998-15002	A 19980128
			US 1996-23290P	P 19960724
			US 1997-899242	A2 19970723
			WO 1999-US1824	W 19990128
IT 202579-57-5P	234776-70-6P	234776-71-7P		
234776-75-1P	234776-76-2P	234776-80-8P		
234776-81-9P	234776-82-0P	234776-83-1P		
234776-84-2P	234776-86-4P	234776-87-5P		
234776-88-6P	234776-89-7P	234776-90-0P		
234776-93-3P	234776-94-4P	234776-98-8P		
234776-99-9P	234777-00-5P	234777-01-6P		
234777-03-8P	234777-06-1P	234777-08-3P		
234777-11-8P	234777-12-9P	234777-13-0P		
234777-14-1P	234777-15-2P	234777-16-3P		
234777-20-9P	234777-21-0P	234777-25-4P		
234777-26-5P	234777-27-6P	234777-28-7P		
234777-29-8P	234777-31-2P	234777-32-3P		
234777-33-4P	234777-34-5P	234777-35-6P		
234777-38-9P	234777-39-0P	234777-44-7P		
234777-45-8P	234777-46-9P	234777-47-0P		


234777-49-2P 234777-52-7P 234777-54-9P
 234777-57-2P 234777-58-3P 234777-59-4P
 234777-60-7P 234777-61-8P 234777-62-9P
 234777-66-3P 234777-67-4P 234777-71-0P
 234777-72-1P 234777-73-2P 234777-74-3P
 234777-75-4P 234777-77-6P 234777-78-7P
 234777-79-8P 234777-80-1P 234777-81-2P
 234777-84-5P 234777-85-6P 234777-89-0P
 234777-90-3P 234777-91-4P 234777-92-5P
 234777-94-7P 234777-97-0P 234777-99-2P
 234778-02-0P 234778-03-1P 234778-04-2P
 234778-11-1P 234778-12-2P 234778-19-9P
 234778-20-2P 234778-27-9P 234778-28-0P
 234778-35-9P 234778-36-0P 234778-43-9P
 234778-44-0P 234778-51-9P 234778-52-0P
 235083-80-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolotriazines and -pyrimidines as CRF antagonists for treatment of anxiety, depression, and other psychiatric, neurol. disorders)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-70-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234776-71-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-75-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-76-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-80-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-81-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-82-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-83-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 234776-84-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-86-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-87-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234776-88-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-
[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-89-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-
[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 234776-90-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-
[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234776-93-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234776-94-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-98-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234776-99-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-00-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-6-chloro-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-01-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-chloro-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-03-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-chloro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-06-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-08-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-11-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-12-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dichlorophenyl)-N-(1-ethoxypropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-13-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-14-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-15-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-2,5,6-trimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 234777-16-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-20-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-21-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)butyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-27-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-28-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-29-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-31-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-32-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-2,5,6-trimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234777-33-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-34-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234777-35-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-38-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-39-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-44-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-45-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-46-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-47-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-49-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-52-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234777-54-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-57-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-60-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 234777-61-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-62-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-66-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-67-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-71-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-72-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-73-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-74-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 234777-75-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-77-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-78-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 234777-79-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-80-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 234777-81-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 234777-84-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 234777-85-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-

[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-89-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-90-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-6-fluoro-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-91-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-92-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-94-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-97-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234777-99-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-6-fluoro-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-02-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-6-fluoro-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-03-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-04-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-6-fluoro-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-11-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-12-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-19-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-20-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-chloro-N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-27-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-28-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-6-fluoro-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-35-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-36-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-6-fluoro-3-(4-methoxy-2,5-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 234778-43-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-44-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)



RN 234778-51-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234778-52-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl- (9CI) (CA INDEX NAME)





RN 235083-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-6-fluoro-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




GI




AB The title compds. [I or II; A = N, CR; Z = N, CR2; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, C1-4 alkyl, C2-4 alkenyl, etc.; R1 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R2 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R3 = H, SH, OH, etc.; R14 = C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists (no data) which are useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POCl3 and N,N-dimethylaniline, followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxy-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R1 = Me; R3 = NHCH(CH2OMe)2; Ar = 2,4-Cl2C6H3].

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:467208 CAPLUS
 DOCUMENT NUMBER: 131:237490
 TITLE: Synthesis and structure-activity relationship of a new series of potent angiotensin II receptor antagonists: pyrazolo[1,5-a]pyrimidine derivatives
 AUTHOR(S): Shiota, Takeshi; Yamamori, Teruo; Sakai, Katsunori; Kiyokawa, Mitsugu; Honma, Tsunetoshi; Ogawa, Masayoshi; Hayashi, Kunio; Ishizuka, Natsuki; Matsumura, Ken-Ichi; Hara, Mariko; Fujimoto, Masafumi; Kawabata, Tomoji; Nakajima, Shigeyuki
 CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi and Co., Ltd., Osaka, 553-0002, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1999), 47(7), 928-938
 CODEN: CPBTAL; ISSN: 0009-2363
 PUBLISHER: Pharmaceutical Society of Japan
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 244127-04-6P
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (synthesis and structure-activity relationship of pyrazolo[1,5-a]pyrimidines as angiotensin II receptor antagonists)
 RN 244127-04-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-ethyl-3-phenyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



IT 244127-51-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and structure-activity relationship of pyrazolo[1,5-a]pyrimidines as angiotensin II receptor antagonists)
 RN 244127-51-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[[5-ethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]methyl]- (9CI) (CA INDEX NAME)



AB We have already reported 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid derivs., which are potent in vitro angiotensin II (AII) antagonists, but have no oral antihypertensive activity. Removal of the carboxylic acid and replacement of the heteroarom. system afforded potent in vitro antagonists. Removal of the carbonyl oxygen and changing the position of the biphenyltetrazole substituent were critical to the display of oral activity. To improve the in vitro and oral activities, modifications were made of the substituents at the 3- and 5- positions of the pyrazolo[1,5-a]pyrimidine. Structure-activity studies showed the Me substituent at the 3-position to be essential for potent in vivo activity. We present the design, syntheses, and biol. data of a series of pyrazolo[1,5-a]pyrimidine derivs., which are orally active AII receptor antagonists.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 48 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:606868 CAPLUS

DOCUMENT NUMBER: 129:302612

TITLE: Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists

AUTHOR(S): Wustrow, David J.; Capiris, Thomas; Rubin, Ronald;
Knobelsdorf, A.; Akunne, Hyacinth; Davis, M. Duff;
MacKenzie, Robert; Pugsley, Thomas A.; Zoski, Kim T.;
Heffner, Thomas G.; Wise, Lawrence D.

CORPORATE SOURCE: Parke-Davis Pharmaceutical Research, Division of
Warner-Lambert Company, Ann Arbor, MI, 48105, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1998),
8(16), 2067-2070

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 214416-28-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)

(preparation of pyrazolo[1,5-a]pyrimidines and their affinity for the human
CRF-1 receptor)

RN 214416-28-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-2,5-
dimethyl- (9CI) (CA INDEX NAME)



AB A series of pyrazolo[1,5-a]pyrimidines was prepared and found to have
affinity for the human CRF-1 receptor. The 3-dimensional structure of one
of the most potent analogs in this series was determined by X-ray crystallog.
and suggests the spatial requirements for potent CRF-1 receptor binding
affinity in this series.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1998:246630 CAPLUS
 DOCUMENT NUMBER: 128:248613
 TITLE: Adenosine reinforcement agents
 INVENTOR(S): Moritoki, Hideki; Iwamoto, Takeshi; Yasuda, Tsuneo
 PATENT ASSIGNEE(S): Ootsuka Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10101672	A2	19980421	JP 1997-208772	19970804
PRIORITY APPLN. INFO.:			JP 1996-207171	A 19960806

OTHER SOURCE(S): MARPAT 128:248613


IT 174859-38-2 174859-40-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(adenosine reinforcement agents)


RN 174859-38-2 CAPLUS

CN Benzamide, N-[5-butyl-2-phenyl-3-[4-(phenylthio)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 174859-40-6 CAPLUS

CN Benzamide, N-(5-butyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = H, lower alkoxy or alkylthio, oxo, etc.; R2 = naphthyl, cycloalkyl, (un)substituted phenoxy, etc.; R3 = H, Ph, lower alkyl; R4 = H, lower alkyl, halo, aralkyl, etc.; R5 = H, lower alkyl; R6 = H, lower alkyl, (un)substituted benzoyl, etc.; Q = CO, SO₂; A = single bond, lower alkylene or alkenylene; n = 0, 1] are presented as adenosine reinforcement agents. I, possessing adenosine reinforcement activity, are useful for prevention and treatment of heart attack, myocardial and brain infarction. Ten compds. of I were tested and showed excellent adenosine reinforcement activity. Formulation containing I were also prepared

L4 ANSWER 50 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:246629 CAPLUS
DOCUMENT NUMBER: 128:248612
TITLE: Nitrogen monooxide synthase inhibitors
INVENTOR(S): Moritoki, Hideki; Iwamoto, Takeshi; Yasuda, Tsuneo
PATENT ASSIGNEE(S): Ootsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 10101671	A2	19980421	JP 1997-207867	19970801
PRIORITY APPLN. INFO.:			JP 1996-209465	A 19960808

OTHER SOURCE(S): MARPAT 128:248612


IT 174859-38-2 174859-40-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyrozolopyrimidine derivs. as nitrogen monooxide synthase inhibitors)


RN 174859-38-2 CAPLUS

CN Benzamide, N-[5-butyl-2-phenyl-3-[4-(phenylthio)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 174859-40-6 CAPLUS

CN Benzamide, N-(5-butyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = H, lower alkoxy or alkylthio, oxo, etc.; R2 = naphthyl, cycloalkyl, (un)substituted phenoxy, etc.; R3 = H, Ph, lower alkyl; R4 = H, lower alkyl, halo, aralkyl, etc.; R5 = H, lower alkyl; R6 = H, lower alkyl, (un)substituted benzoyl, etc.; Q = CO, SO₂; A = single bond, lower alkylene or alkenylene; n = 0, 1] are presented as NO synthase inhibitors. I are useful for prevention and treatment of septicemia. 14 Compds. of I were tested and showed excellent NO synthase inhibitory activity. Formulation containing I were also prepared

L4 ANSWER 51 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:163594 CAPLUS
DOCUMENT NUMBER: 128:204902
TITLE: Preparation of heterobicyclic derivatives as CRF antagonists
INVENTOR(S): Chen, Yuhpyng Liang
PATENT ASSIGNEE(S): Pfizer Inc., USA; Chen, Yuhpyng Liang
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808847	A1	19980305	WO 1997-IB922	19970725
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2263566	AA	19980305	CA 1997-2263566	19970725
CA 2263566	C	20030909		
AU 9734561	A1	19980319	AU 1997-34561	19970725
AU 735401	B2	20010705		
EP 923582	A1	19990623	EP 1997-930697	19970725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9711970	A	19990824	BR 1997-11970	19970725
CN 1227554	A	19990901	CN 1997-197027	19970725
JP 2000502723	T2	20000307	JP 1998-511429	19970725
JP 3621706	B2	20050216		
TR 9900389	T2	20000621	TR 1999-389	19970725
NZ 333302	A	20000825	NZ 1997-333302	19970725
HR 970454	B1	20021031	HR 1997-970454	19970822
TW 575573	B	20040211	TW 1997-86112194	19970825
ZA 9707687	A	19990301	ZA 1997-7687	19970827
NO 9900927	A	19990226	NO 1999-927	19990226
NO 313636	B1	20021104		
KR 2000035934	A	20000626	KR 1999-701674	19990227
US 2001007867	A1	20010712	US 1999-242682	19991213
US 2002151713	A1	20021017	US 2002-160206	20020530
US 6900217	B2	20050531		
US 2005009823	A1	20050113	US 2004-762742	20040122
JP 2005047930	A2	20050224	JP 2004-273978	20040921
PRIORITY APPLN. INFO.:			US 1996-25039P	P 19960828
			JP 1998-511429	A3 19970725
			WO 1997-IB922	W 19970725
			US 1999-242682	A1 19991213
			US 2002-160206	A3 20020530


OTHER SOURCE(S): MARPAT 128:204902

IT 203924-40-7P 203924-41-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterobicyclic derivs. as CRF antagonists)


RN 203924-40-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)





RN 203924-41-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-5-methyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; A = N or CR7; D<E = O, S, NR8, CO, CS, CR4R6; G = N or C; 1 of J,K = N and the other = C; J = K =C; R = NR1R2, COR2, CR1R2R10, etc.; R1 = (un)substituted alkyl, -alkenyl, -alkynyl, etc.; R2 = alk(en)yl, (hetero)aryl(alkyl), etc.; R3 = H, halo, alkyl, alkoxy, etc.; R4 = H, halo, alkyl, alkoxy, etc.; R5 = substituted (hetero)aryl; R6 = H, Me, Et; R7 = H, halo, alkyl, alkoxy, etc.; R8 = H or alkyl; R10 = H, OH, OMe, F] were prepared as CRF antagonists (no data). Thus, OHCCHR5CN (R5 = 2,4,6-trimethylphenyl throughout) was cyclocondensed with H2NNH2 and the pyrazole product cyclocondensed with MeCOCH2CO2Me to give pyrazolopyrimidine II (R = OH) which was treated with POCl3 and the product etherified by Et2CHOH to give II (R = OCHEt2).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1998:87733 CAPLUS
 DOCUMENT NUMBER: 128:154103
 TITLE: Preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): Arvanitis, Argyrios Georgious; Chorvat, Robert John
 PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USA
 SOURCE: PCT Int. Appl., 225 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803510	A1	19980129	WO 1997-US13072	19970723
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2259583	AA	19980129	CA 1997-2259583	19970723
CA 2532925	AA	19980129	CA 1997-2532925	19970723
AU 9738942	A1	19980210	AU 1997-38942	19970723
AU 747708	B2	20020523		
EP 915880	A1	19990519	EP 1997-936222	19970723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1225637	A	19990811	CN 1997-196525	19970723
CN 1104432	B	20030402		
BR 9710544	A	19990817	BR 1997-10544	19970723
US 6124289	A	20000926	US 1997-899242	19970723
JP 2002513382	T2	20020508	JP 1998-507233	19970723
EE 4316	B1	20040615	EE 1999-19	19970723
ZA 9706603	A	19990125	ZA 1997-6603	19970724
TW 542827	B	20030721	TW 1997-86110640	19970725
LV 12292	B	19991120	LV 1999-13	19990120
NO 9900264	A	19990310	NO 1999-264	19990121
NO 315610	B1	20030929		
LT 4680	B	20000725	LT 1999-8	19990125
CN 1327793	A	20011226	CN 2001-120849	20010530
AU 773039	B2	20040513	AU 2002-23236	20020312
CN 1388126	A	20030101	CN 2002-118589	20020425
JP 2005097257	A2	20050414	JP 2004-216483	20040723
PRIORITY APPLN. INFO.:			US 1996-23290P	P 19960724
			US 1996-686047	A 19960724
			US 1997-899242	A 19970723
			AU 1997-38942	A3 19970723
			CA 1997-2259583	A3 19970723
			JP 1998-507233	A3 19970723
			WO 1997-US13072	W 19970723

OTHER SOURCE(S): MARPAT 128:154103
 IT 202579-57-5P 202579-60-0P 202579-62-2P
 202579-63-3P 202579-64-4P 202579-65-5P
 202579-69-9P 202579-73-5P 202579-74-6P
 202579-75-7P 202579-77-9P 202579-78-0P
 202579-80-4P 202579-81-5P 202579-82-6P
 202579-84-8P 202579-87-1P 202579-91-7P
 202579-92-8P 202579-94-0P 202579-95-1P
 202580-25-4P 202580-26-5P 202580-28-7P
 202580-48-1P 202580-52-7P 202580-53-8P

202580-54-9P 202580-55-0P 202580-56-1P


202580-57-2P 202580-58-3P 202580-59-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists)


RN 202579-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-63-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-64-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-65-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-69-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-78-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-80-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-81-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-82-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 202579-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202579-87-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-92-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-94-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202579-95-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-25-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-28-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-48-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2,3-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-52-7 CAPLUS
 CN 1,3-Propanediol, 2-[[3-(2,4-dichlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 202580-53-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 202580-54-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-55-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-2,5-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 202580-56-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-57-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[3-methoxy-1-(methoxymethyl)propyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 202580-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)





RN 202580-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methylphenyl)-N-[1-(methoxymethyl)butyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, C1-4 alkyl, C2-4 alkenyl, etc.; R₁ = H, C1-4 alkyl, C2-4 alkenyl, etc.; R₂ = H, C1-4 alkyl, C2-4 alkenyl, etc.; R₃ = H, SH, OH, etc.; R₁₄ = C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POC13 and N,N-dimethylaniline followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxypropyl-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R₁ = Me; R₃ = NHCH(CH₂OMe)₂; Ar = 2,4-C₁₂H₃].

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 53 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:542450 CAPLUS
DOCUMENT NUMBER: 127:220669
TITLE: Pyrazolopyrimidines as CRF receptor antagonists
INVENTOR(S): Chen, Chen; Webb, Thomas R.; McCarthy, James R.;
Moran, Terence J.; Wilcoxon, Keith M.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.; Neurocrine
Biosciences, Inc.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729109	A1	19970814	WO 1997-EP459	19970130
W: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2233285	AA	19970814	CA 1997-2233285	19970130
AU 9715991	A1	19970828	AU 1997-15991	19970130
AU 713673	B2	19991209		
EP 880523	A1	19981202	EP 1997-902295	19970130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1205009	A	19990113	CN 1997-191382	19970130
CN 1090189	B	20020904		
BR 9707391	A	19990720	BR 1997-7391	19970130
NZ 330119	A	20000228	NZ 1997-330119	19970130
JP 2000503661	T2	20000328	JP 1997-528123	19970130
JP 3356291	B2	20021216		
JP 2002121194	A2	20020423	JP 2001-265611	19970130
EE 4282	B1	20040415	EE 1998-124	19970130
TW 449599	B	20010811	TW 1997-86101373	19970205
ZA 9700989	A	19980806	ZA 1997-989	19970206
NO 9801357	A	19980803	NO 1998-1357	19980325
NO 310292	B1	20010618		
US 2003125341	A1	20030703	US 1999-117717	19990302
US 6664261	B2	20031216		
US 2004127483	A1	20040701	US 2003-665740	20030919
PRIORITY APPLN. INFO.:			US 1996-11279P	P 19960207
			US 1996-27688P	P 19961008
			JP 1997-528123	A3 19970130
			WO 1997-EP459	W 19970130
			US 1999-117717	A1 19990302

OTHER SOURCE(S): MARPAT 127:220669

IT 16142-51-1P 195054-42-3P 195054-43-4P
195054-44-5P 195054-45-6P 195054-46-7P
195054-47-8P 195054-48-9P 195054-49-0P
195054-50-3P 195054-51-4P 195054-52-5P
195054-53-6P 195054-54-7P 195054-71-8P
195054-72-9P 195054-73-0P 195054-75-2P
195054-90-1P 195055-15-3P 195055-18-6P


195055-21-1P 195055-43-7P 195055-44-8P
195055-45-9P 195055-46-0P 195055-47-1P
195055-53-9P 195055-54-0P 195055-55-1P
195055-82-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)


RN 16142-51-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,2,5-trimethyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 195054-42-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-43-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 195054-44-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1,1-dimethylethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-45-6 CAPLUS
 CN 1-Propanol, 3-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195054-46-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-47-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-48-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 195054-49-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 195054-50-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1,2-dimethylpropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-51-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1,3-dimethylbutyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 195054-52-5 CAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-4-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195054-53-6 CAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-4-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195054-54-7 CAPLUS

CN 1-Butanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-


yl]amino]-3-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195054-71-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-72-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-methylethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-73-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpentyl)-5-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-75-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[(3-methoxyphenyl)methyl]-5-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-90-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-butyl-3-(2,4-dichlorophenyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 195055-15-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(2-methoxy-1-methylethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195055-18-6 CAPLUS
 CN 1-Hexanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 195055-21-1 CAPLUS
 CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-43-7 CAPLUS
 CN 1-Hexanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-44-8 CAPLUS

CN 1-Pentanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 195055-45-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chlorophenyl)-2,5-dimethyl-N-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)




RN 195055-46-0 CAPLUS

CN 1-Pentanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-4-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 195055-47-1 CAPLUS
 CN 1-Hexanol, 2-[[3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-53-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-54-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 195055-55-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1,3-dimethylbutyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 195055-82-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



GI




AB Title compds. I [R = (un)substituted Ph, pyridyl; R1 = substituted NH2, (un)substituted alkoxy; R2 = alkyl, alkoxy, alkylthio; R3 = H, alkyl,

alkylsulfonyl, alkylsulfoxy, alkylthio] having CRF receptor antagonistic properties, were prepared. Thus, I [R = 2,4-Cl₂C₆H₃, R₁ = N-propyl-N-cyclopropylmethylamino, R₂ = Me, R₃ = H, II] was obtained by treating 3-amino-4-(2,4-dichlorophenyl)pyrazole with MeCOCH₂CO₂Et, chlorinating I [R = 2,4-Cl₂C₆H₃, R₁ = OH, R₂ = Me, R₃ = H] and aminating I [R₁ = Cl]. II had a K_i for CRF receptor inhibition of <250 nM.

L4 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1996:196727 CAPLUS
DOCUMENT NUMBER: 124:261026
TITLE: Preparation and formulation of pyrazolopyrimidine derivatives as analgesics
INVENTOR(S): Shoji, Yasuo; Inoue, Makoto; Okamura, Takashi; Hashimoto, Kinji; Ohara, Masayuki; Yasuda, Tsuneo
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9535298	A1	19951228	WO 1995-JP1104	19950605
W: AU, CA, CN, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2169719	AA	19951228	CA 1995-2169719	19950605
CA 2169719	C	20020416		
AU 9525765	A1	19960115	AU 1995-25765	19950605
AU 680370	B2	19970724		
EP 714898	A1	19960605	EP 1995-920260	19950605
EP 714898	B1	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1131948	A	19960925	CN 1995-190760	19950605
CN 1046730	B	19991124		
JP 08311068	A2	19961126	JP 1995-137878	19950605
JP 3163412	B2	20010508		
JP 08310951	A2	19961126	JP 1995-137890	19950605
JP 3163413	B2	20010508		
AT 208776	E	20011115	AT 1995-920260	19950605
ES 2164153	T3	20020216	ES 1995-920260	19950605
PT 714898	T	20020429	PT 1995-920260	19950605
US 5707997	A	19980113	US 1996-602824	19960221
PRIORITY APPLN. INFO.:			JP 1994-138635	A 19940621
			JP 1995-53997	A 19950314
			WO 1995-JP1104	W 19950605
OTHER SOURCE(S): MARPAT 124:261026				
IT 174859-38-2P	174859-40-6P			
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of pyrazolopyrimidine derivs. as analgesics)				
RN 174859-38-2	CAPLUS			
CN	Benzamide, N-[5-butyl-2-phenyl-3-[4-(phenylthio)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)			




RN 174859-40-6 CAPLUS


CN Benzamide, N-(5-butyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



GI



I




II

AB The title compds. I [R1 represents hydrogen, lower alkyl, cycloalkyl,


thienyl, furyl, lower alkenyl or phenyl; R2 represents naphthyl, cycloalkyl, furyl, thienyl, pyridyl, phenoxy or phenyl; R3 represents hydrogen, Ph or lower alkyl; R4 represents hydrogen, lower alkyl, lower alkoxy carbonyl, phenyl-substituted lower alkyl, Ph or halogen; R5 represents hydrogen or lower alkyl; R6 represents hydrogen, lower alkyl, phenyl-substituted lower alkyl or benzoyl; Q represents carbonyl or sulfonyl; A represents a single bond, lower alkylene or lower alkenylene; and n represents 0 or 1] are prepared. The title compound II (preparation given) at 3 mg/Kg orally showed potent analgesic activity in rats.

ACCESSION NUMBER: 1993:213102 CAPLUS
 DOCUMENT NUMBER: 118:213102
 TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives
 antiinflammatory agents
 INVENTOR(S): Inoue, Makoto; Hashimoto, Kinji; Kuwahara, Toshiko;
 Sugimoto, Yukio; Uesako, Takuji; Funato, Toshiaki
 PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9218504	A1	19921029	WO 1991-JP1043	19910806
W: AU, CA, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2107479	AA	19921023	CA 1991-2107479	19910806
CA 2107479	C	19971216		
AU 9182958	A1	19921117	AU 1991-82958	19910806
AU 651986	B2	19940811		
EP 591528	A1	19940413	EP 1991-913666	19910806
EP 591528	B1	19981223		
R: AT, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
AT 174917	E	19990115	AT 1991-913666	19910806
ES 2126573	T3	19990401	ES 1991-913666	19910806
JP 05070353	A2	19930323	JP 1992-55370	19920313
US 5688949	A	19971118	US 1993-133086	19931007
PRIORITY APPLN. INFO.:			JP 1991-90707	A 19910422
			WO 1991-JP1043	A 19910806
OTHER SOURCE(S):			MARPAT 118:213102	
IT 137739-40-3P 137739-41-4P 137739-43-6P				
137739-44-7P 137739-55-0P 137739-56-1P				
137739-59-4P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of, as antiinflammatory agent)				
RN 137739-40-3 CAPLUS				
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (9CI) (CA INDEX NAME)				




RN 137739-41-4 CAPLUS
 CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 137739-43-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[[2-(methoxycarbonyl)phenyl]amino]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137739-44-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[[4-hydroxy-3-(methoxycarbonyl)phenyl]amino]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137739-55-0 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (9CI) (CA INDEX NAME)



RN 137739-56-1 CAPLUS


CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, monosodium salt (9CI) (CA INDEX NAME)







● Na

RN 137739-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[(3-carboxy-4-hydroxyphenyl)amino]-3-phenyl- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1-R4 = H, CO₂H, Ph, alkoxycarbonyl, alkyl, cycloalkyl, etc.; R1R2 = alkylene; R5 = SR₆, NR₇R₈ (wherein R₆ = pyridyl, Ph or substituted Ph; R₇, R₈ = H, Ph or substituted Ph, etc.)] are prepared A suspension of Cl compound II (R = Cl) 3.5, aniline salt III 6.0, and PhNEt₂ 6.0 in MePh was heated at 120° to give 4.7 g IV, which showed IC₅₀ of 3 + 10⁻⁷M against cyclooxygenase. IV showed 65.0% inhibition against cyclooxygenase at 3 + 10⁻⁷M, vs. 12.4% with indomethacin.

ACCESSION NUMBER: 1992:6580 CAPLUS
 DOCUMENT NUMBER: 116:6580
 TITLE: Preparation of pyrazolo[1,5-a]pyrimidine derivatives
 as drugs
 INVENTOR(S): Inoue, Makoto; Hashimoto, Kinji
 PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03204877	A2	19910906	JP 1990-289769	19901025
JP 2585462	B2	19970226		
PRIORITY APPLN. INFO.:			JP 1989-277566	A1 19891025


OTHER SOURCE(S): MARPAT 116:6580

IT 137739-40-3P 137739-41-4P 137739-43-6P
 137739-44-7P 137739-55-0P 137739-56-1P
 137739-59-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as drug)


RN 137739-40-3 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(5-methyl-3-phenylpyrazolo[1,5-
 a]pyrimidin-7-yl)amino]- (9CI) (CA INDEX NAME)




RN 137739-41-4 CAPLUS

CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-,
 methyl ester (9CI) (CA INDEX NAME)




RN 137739-43-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[[2-(methoxycarbonyl)phenyl]amino]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 137739-44-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[[4-hydroxy-3-(methoxycarbonyl)phenyl]amino]-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 137739-55-0 CAPLUS


CN Benzoic acid, 2-hydroxy-5-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-

yl)amino]- (9CI) (CA INDEX NAME)



RN 137739-56-1 CAPLUS


CN Benzoic acid, 2-[(5-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 137739-59-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid, 7-[(3-carboxy-4-hydroxyphenyl)amino]-3-phenyl- (9CI) (CA INDEX NAME)




GI




AB The title compds. [I; R1-R4 = H, CO₂H, alkoxy carbonyl, Ph, (HO-, HO₂C-, or alkoxy carbonyl-substituted)alkyl, cycloalkyl; or R1R2 = alkylene; R5 = SR6, NR7R8; R6 = pyridyl, (1-3 HO- or alkyl-substituted) Ph; R7, R8 = H, (1-3 HO-, alkyl-, alkoxy carbonyl-, or HO₂C-substituted) Ph; or NR7R8 = 1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, (un)substituted 1-piperazinyl], useful as antiinflammatories, antirheumatics, antiasthmatics, allergy inhibitors, antipyretics, and analgesics and for improvement of ischemia (no data), are prepared Thus, a suspension of 1.0 g 7-chloropyrazolo[1,5-pyrimidine, 1.8 g 3,5-di-tert-butyl-4-hydroxyaniline-HCl, and 2.3 mL PhNEt₂ in PhMe was heated 30 min at 120° to give 890 mg I (R1-R4 = H, R5 = 3,5-di-tert-butyl-4-hydroxyphenylamino). A total of 48 I were prepared

L4 ANSWER 57 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1986:47662 CAPLUS
 DOCUMENT NUMBER: 104:47662
 TITLE: Purine analog inhibitors of xanthine oxidase -
 structure activity relationships and proposed binding
 of the molybdenum cofactor
 AUTHOR(S): Robins, Roland K.; Revankar, Ganapathi R.; O'Brien,
 Darrell E.; Springer, Robert H.; Novinson, Thomas;
 Albert, Anthony; Senga, Keitaro; Miller, Jon P.;
 Streeter, David G.
 CORPORATE SOURCE: Cancer Res. Cent., Brigham Young Univ., Provo, UT,
 84602, USA
 SOURCE: Journal of Heterocyclic Chemistry (1985), 22(3),
 601-34
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 104:47662
 IT 99898-59-6P 99898-61-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of and xanthine oxidase inhibition by)
 RN 99898-59-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(3-methylphenyl)- (9CI) (CA
 INDEX NAME)




RN 99898-61-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-methylphenyl)-N-propyl- (9CI) (CA
 INDEX NAME)



AB An updated study of structure-activity relations and binding to xanthine oxidase of hypoxanthine analogs is presented. In view of the recent elucidation of the pterin cofactor and the proposed binding of this factor to the Mo ion in xanthine oxidase, a detailed mechanism of xanthine oxidase oxidation of hypoxanthine and xanthine is proposed. Three types of substrate binding are viewed for xanthine oxidase: the binding of xanthine to xanthine oxidase is termed Type I binding, the binding of hypoxanthine is termed Type II binding, and the specific binding of alloxanthine is called Type III binding. These 3 types of substrate binding were determined for the most potent known inhibitors of xanthine oxidase, and these

inhibitors were classified as to the type of inhibitor binding most likely to be associated with specific enzyme inhibition. The structural requirements for each type of binding can be clearly seen to correlate with the inhibitory activity observed. The chemical syntheses of the new 3-phenyl- and 3-substituted phenylpyrazolo[1,5-a]pyrimidines with various substituents are reported. The syntheses of various 8-phenyl-2-substituted pyrazolo[1,5-a]-s-triazines, certain s-triazolo[1,5-a]-s-triazines and s-triazolo[1,5-a]pyrimidine derivs. prepared in connection with the present study are also described.


L4 ANSWER 58 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1971:405833 CAPLUS
 DOCUMENT NUMBER: 75:5833
 TITLE: Acyl enamines. 18. Reaction of
 phenylcyanoacetaldehyde with hydrazine
 AUTHOR(S): Eiden, Fritz; Evers, G.
 CORPORATE SOURCE: Pharm. Inst., Freie Univ. Berlin, Berlin, Fed. Rep.
 Ger.
 SOURCE: Archiv der Pharmazie und Berichte der Deutschen
 Pharmazeutischen Gesellschaft (1971), 304(2), 121-5
 CODEN: APBDAJ; ISSN: 0376-0367
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 IT 32016-26-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 32016-26-5 CAPLUS
 CN Acetamide, N-(3,6-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI) (CA INDEX
 NAME)



AB Reaction of $\text{PhCH}(\text{CN})\text{CHO}$ with $\text{H}_2\text{NNH}_2 \cdot \text{H}_2\text{O}$ in C_6H_6 in the presence of
 $p\text{-MeC}_6\text{H}_4\text{SO}_3\text{H}$ gave 73% I (and II ($\text{R} = \text{R}_1 = \text{H}$) (III) by-product) but no
 $\text{PhCH}(\text{CN})\text{CH}:\text{NN}:\text{CHCH}(\text{CN})\text{Ph}$ (described by E. L. Anderson, et al. (1964)).
 Heating III in Ac_2O and concentrated H_2SO_4 gave 63% II ($\text{R} = \text{R}_1 = \text{Ac}$) and some
 II ($\text{R} = \text{H}$, $\text{R}_1 = \text{Ac}$).

ACCESSION NUMBER: 1971:22872 CAPLUS
 DOCUMENT NUMBER: 74:22872
 TITLE: 7-Aminoalkylaminopyrazolo[1,5-a]pyrimidine derivatives
 INVENTOR(S): Takamizawa, Akira
 PATENT ASSIGNEE(S): Shionogi and Co., Ltd.
 SOURCE: Jpn. Tokkyo Koho, 3 pp.
 CODEN: JAXXAD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	JP 45030335	B4	19701001	JP	19661214
IT	30156-81-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	30156-81-1 CAPLUS				
CN	1-Piperidineacetamide, N-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI) (CA INDEX NAME)				



GI For diagram(s), see printed CA Issue.
 AB I is treated with an amine and the resulting II reduced to manufacture III, useful as an antipyretic, analgesic, and antiinflammatory drug. In an example, I in CHCl₃ is refluxed 5 hr with piperidine to give II (A = piperidino), m. 195-6°. Similarly prepared are the following II (A given): morpholino; NMe₂. III (A = piperidino) in THF is dropped into a suspension of LiAlH₄ in THF and the mixture refluxed 4 hr to give III (A = piperidino). Similarly prepared are the following III (A given): morpholino; NMe₂.

ACCESSION NUMBER: 1968:114635 CAPLUS
 DOCUMENT NUMBER: 68:114635
 TITLE: 7-Haloacylamino-pyrazolo[1,5-a]pyrimidines
 INVENTOR(S): Takamizawa, Akira
 PATENT ASSIGNEE(S): Shionogi and Co., Ltd.
 SOURCE: Jpn. Tokkyo Koho, 2 pp.
 CODEN: JAXXAD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	JP 42016314	B4	19670904	JP	19640629
IT	17560-60-0P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	17560-60-0 CAPLUS				
CN	Acetamide, 2-chloro-N-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI) (CA INDEX NAME)				




AB 2,3-Dimethyl-7-aminopyrazolo[1,5-a]pyrimidine (5.7 g.) in 40 ml. Me₂NCHO is treated with 4 g. ClCH₂COCl with ice-cooling and the whole heated to give 1.94 g. 2,3-dimethyl-7-chloroacetamidopyrazolo[1,5-a]pyrimidine, m. 175° (MeOH). Similarly prepared are the following R-substituted-7-chloroacetamidopyrazolo[1,5-a]pyrimidines (R and m.p. given): 2,3,6-trimethyl, 139-41°; 2,5-dimethyl-3-phenyl, 158-9°. The products are then subjected to aminolysis to give antipyretic, analgesic, and antiphlogistic drugs.


L4 ANSWER 61 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1967:508663 CAPLUS
DOCUMENT NUMBER: 67:108663
TITLE: 7-Methylaminopyrazolo[1,5-a]pyrimidine derivatives
INVENTOR(S): Takamizawa, Akira; Hamashima, Yoshio
PATENT ASSIGNEE(S): Shionogi and Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	JP 42011753	B4	19670704	JP	19640120
IT	16142-50-0P 16142-51-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	16142-50-0 CAPLUS				
CN	Formamide, N-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI) (CA INDEX NAME)				



RN 16142-51-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,2,5-trimethyl-3-phenyl- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.
AB cf. preceding abstract Manufacture of Ia (I where X is NHMe), useful as sedative and antiphlogistic agents, starting from Ib (I where X is NH₂) via Ic (I where X is NHCHO) is described. In an example, 5 ml. acid anhydride of a mixture of HCO₂H and Ac₂O is added to 1 g. ice-cooled Ib (R₁ = R₂ = Me, R₃ = R₄ = H), the whole let stand for 1.5 days, concentrated in vacuo, and the residue recrystd. (Me₂CO) to give 0.95 g. Ic (R₁ = R₂ = Me, R₃ = R₄ = H), pale green, m. 189°. Similarly prepared are the following Ic (R₁, R₂, R₃, R₄, and m.p. given): Me, Me, H, Me (pale green), 183°; Me, Ph, Me, H (pale yellow), 184° (decomposition); PhCH₂, Me, Me, H, 131-2°. Ic (R₁ = R₂ = Me, R₃ = R₄ = H) (1 g.) in 30 ml.

tetrahydrofuran is added to icecooled mixture of 0.7 g. LiAlH_4 and 50 ml. tetrahydrofuran, the mixture heated at 70° for 5 hrs., NaOH solution added, the tetrahydrofuran layer separated and concentrated, and the residue extracted

with CHCl_3 to give 0.83 g. Ia ($\text{R}_1 = \text{R}_2 = \text{Me}$, $\text{R}_3 = \text{R}_4 = \text{H}$), m. 146° (Et_2O). Similarly prepared are the following Ia (R_1 , R_2 , R_3 , R_4 , and m.p. given): Me, Me, H, Me, 157° ; Me, Ph, Me, H, $190-1^\circ$; PhCH_2 , Me, Me, H, (oil) (picrate m. $207-8^\circ$).

L4 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1967:410663 CAPLUS

DOCUMENT NUMBER: 67:10663

TITLE: The electrocardiographic picture in the acute experimental poisoning from organic phosphorus compounds

AUTHOR(S): Orlando, E.; Raffi, G. B.; Zini, C.

CORPORATE SOURCE: Ist. Med., Univ. Bologna, Bologna, Italy

SOURCE: Lavoro Umano (1966), 18(11), 493-501

CODEN: LAUMAL; ISSN: 0023-9127

DOCUMENT TYPE: Journal


LANGUAGE: Italian

IT 16142-50-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16142-50-0 CAPLUS


CN Formamide, N-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)- (8CI)
(CA INDEX NAME)




AB A study of the electrocardiographic changes effected by parathion, administered i.v. into rabbits at an acute poisoning dose of 12.5 mg./kg. body weight, suggested that electrolyte imbalances effected by organic P compds. play a role in the genesis of these electrocardiographic changes.

ACCESSION NUMBER: 1966:75800 CAPLUS
 DOCUMENT NUMBER: 64:75800
 ORIGINAL REFERENCE NO.: 64:14196h,14197a-b
 TITLE: 7-Substituted carbonylaminopyrazolo[1,5-
 α]pyrimidine derivatives
 INVENTOR(S): Takamizawa, Akira; Hamashima, Yoshio
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd.
 SOURCE: 3 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 41001864	B4	19660209	JP	19630907
PRIORITY APPLN. INFO.:				JP	19630907
IT	5299-74-1, Urea, 3-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-1,1-dimethyl- 5299-76-3, Pyrazolo[1,5-a]pyrimidine-7-carbamic acid, 2,5-dimethyl-3-phenylthio-, S-ethyl ester 5313-71-3, Pyrazolo[1,5-a]pyrimidine-7-carbamic acid, 2,5-dimethyl-3-phenyl-, ethyl ester (preparation of)				
RN	5299-74-1 CAPLUS				
CN	Urea, 3-(2,5-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-1,1-dimethyl- (7CI, 8CI) (CA INDEX NAME)				



RN 5299-76-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-7-carbamic acid, 2,5-dimethyl-3-phenylthio-, S-ethyl ester (7CI, 8CI) (CA INDEX NAME)



RN 5313-71-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine-7-carbamic acid, 2,5-dimethyl-3-phenyl-, ethyl ester (7CI, 8CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB Manufacture of I, useful as tranquilizer and antiinflammatory agents, is described. Thus, a mixture of 1 g. 2,3-dimethyl-7-aminopyrazolo[1,5-a]pyrimidine and 0.67 g. ClCO₂Et in 20 ml. Me₂CO is heated at 100° for 4 hrs. in a sealed tube, cooled, filtered, the filtrate extracted with CHCl₃, and the extract concentrated to give 0.83 g. I (R₁ = R₂ = Me, R₃ = H,

R₄ = OEt), columns, m. 113° (Et₂O); hydrochloride m. 188°. Similarly prepared are the following I (R₁, R₂, R₃, R₄, and m.p. given): Me, Me, H, NMe₂, 163° (hydrochloride m. 210-13°); Me, Me, H, morpholino, -- (hydrochloride m. 208°); Me, Me, H, piperidino, 136°; Me, Ph, Me, OEt, 148-9°; Me, Ph, Me, NMe₂, 148-50°; Bz, Me, Me, OEt, 92°; Me, Ph, Me, SEt, 105°; Bz, Me, Me, SEt, 98-9°; Bz, Me, Me, NMe₂, 137-8°; Bz, Me, Me, piperidino, 118-19°.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	322.85	490.00
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-47.25	-47.25

STN INTERNATIONAL LOGOFF AT 18:40:44 ON 15 JUN 2006